{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T20:34:23Z","timestamp":1794170063083,"version":"4.8.0"},"reference-count":469,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Liaoning Province Joint Fund Project General Funding Scheme Project","award":["2023-MSLH-161"],"award-info":[{"award-number":["2023-MSLH-161"]}]},{"name":"National Natural Science Foundation of China, Youth Science Foundation Project","award":["82103056"],"award-info":[{"award-number":["82103056"]}]},{"name":"Liaoning Provincial Department of Science and Technology, Liaoning Provincial Applied Basic Research Project","award":["2022JH2\/101300045"],"award-info":[{"award-number":["2022JH2\/101300045"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Ovarian cancer (OC) is the most lethal gynecological malignancy worldwide, characterized by heterogeneity at the molecular, cellular and anatomical levels. Most patients are diagnosed at an advanced stage, characterized by widespread peritoneal metastasis. Despite optimal cytoreductive surgery and platinum-based chemotherapy, peritoneal spread and recurrence of OC are common, resulting in poor prognoses. The overall survival of patients with OC has not substantially improved over the past few decades, highlighting the urgent necessity of new treatment options. Unlike the classical lymphatic and hematogenous metastasis observed in other malignancies, OC primarily metastasizes through widespread peritoneal seeding. Tumor cells (the \u201cseeds\u201d) exhibit specific affinities for certain organ microenvironments (the \u201csoil\u201d), and metastatic foci can only form when there is compatibility between the \u201cseeds\u201d and \u201csoil.\u201d Recent studies have highlighted the tumor microenvironment (TME) as a critical factor influencing the interactions between the \u201cseeds\u201d and \u201csoil,\u201d with ascites and the local peritoneal microenvironment playing pivotal roles in the initiation and progression of OC. Prior to metastasis, the interplay among tumor cells, immunosuppressive cells, and stromal cells leads to the formation of an immunosuppressive pre-metastatic niche in specific sites. This includes characteristic alterations in tumor cells, recruitment and functional anomalies of immune cells, and dysregulation of stromal cell distribution and function. TME-mediated crosstalk between cancer and stromal cells drives tumor progression, therapy resistance, and metastasis. In this review, we summarize the current knowledge on the onset and metastatic progression of OC. We provide a comprehensive discussion of the characteristics and functions of TME related to OC metastasis, as well as its association with peritoneal spread. We also outline ongoing relevant clinical trials, aiming to offer new insights for identifying potential effective biomarkers and therapeutic targets in future clinical practice.<\/jats:p>","DOI":"10.1186\/s12967-025-06508-0","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:22:47Z","timestamp":1747225367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Role of tumor microenvironment in ovarian cancer metastasis and clinical advancements"],"prefix":"10.1186","volume":"23","author":[{"given":"Yang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"issue":"1","key":"6508_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"6508_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"6508_CR3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2217\/imt.11.20","volume":"3","author":"CC Preston","year":"2011","unstructured":"Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 2011;3(4):539\u201356.","journal-title":"Immunotherapy"},{"key":"6508_CR4","doi-asserted-by":"publisher","first-page":"770983","DOI":"10.3389\/fmolb.2022.770983","volume":"9","author":"MV Iurova","year":"2022","unstructured":"Iurova MV, Chagovets VV, Pavlovich SV, Starodubtseva NL, Khabas GN, Chingin KS, Tokareva AO, Sukhikh GT, Frankevich VE. Lipid alterations in Early-Stage High-Grade serous ovarian Cancer. Front Mol Biosci. 2022;9:770983.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"6508_CR5","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/s41467-017-00962-1","volume":"8","author":"SI Labidi-Galy","year":"2017","unstructured":"Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, et al. High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun. 2017;8(1):1093.","journal-title":"Nat Commun"},{"key":"6508_CR6","doi-asserted-by":"crossref","unstructured":"Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian Cancer immunotherapy and personalized medicine. Int J Mol Sci 2021, 22(12).","DOI":"10.3390\/ijms22126532"},{"key":"6508_CR7","doi-asserted-by":"crossref","unstructured":"Zhang J, Li XB, Ji ZH, Ma R, Bai WP, Li Y. Cytoreductive Surgery plus Hyperthermic Intraperitoneal Chemotherapy Improves Survival with Acceptable Safety for Advanced Ovarian Cancer: A Clinical Study of 100 Patients. Biomed Res Int 2021, 2021:5533134.","DOI":"10.1155\/2021\/9789613"},{"issue":"5","key":"6508_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"1","key":"6508_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31\u201346.","journal-title":"Cancer Discov"},{"issue":"suppl8","key":"6508_CR10","doi-asserted-by":"publisher","first-page":"viii61","DOI":"10.1093\/annonc\/mdx443","volume":"28","author":"EA Eisenhauer","year":"2017","unstructured":"Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28(suppl8):viii61\u20135.","journal-title":"Ann Oncol"},{"issue":"7","key":"6508_CR11","doi-asserted-by":"publisher","first-page":"C444","DOI":"10.1152\/ajpcell.00188.2015","volume":"309","author":"TL Yeung","year":"2015","unstructured":"Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in Cancer metastasis. Am J Physiol Cell Physiol. 2015;309(7):C444\u2013456.","journal-title":"Am J Physiol Cell Physiol"},{"key":"6508_CR12","doi-asserted-by":"crossref","unstructured":"Fucikova J, Coosemans A, Orsulic S, Cibula D, Vergote I, Galluzzi L, Spisek R. Immunological configuration of ovarian carcinoma: features and impact on disease outcome. J Immunother Cancer 2021, 9(10).","DOI":"10.1136\/jitc-2021-002873"},{"issue":"2","key":"6508_CR13","doi-asserted-by":"publisher","first-page":"188361","DOI":"10.1016\/j.bbcan.2020.188361","volume":"1873","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Wang C, Zhou S. Targeting tumor microenvironment in ovarian cancer: premise and promise. Biochim Biophys Acta Rev Cancer. 2020;1873(2):188361.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"9","key":"6508_CR14","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/cas.12987","volume":"107","author":"S Kim","year":"2016","unstructured":"Kim S, Kim B, Song YS. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer. Cancer Sci. 2016;107(9):1173\u20138.","journal-title":"Cancer Sci"},{"key":"6508_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fonc.2017.00024","volume":"7","author":"T Worzfeld","year":"2017","unstructured":"Worzfeld T, von Pogge E, Huber M, Adhikary T, Wagner U, Reinartz S, Muller R. The unique molecular and cellular microenvironment of ovarian Cancer. Front Oncol. 2017;7:24.","journal-title":"Front Oncol"},{"key":"6508_CR16","doi-asserted-by":"publisher","first-page":"154739","DOI":"10.1016\/j.prp.2023.154739","volume":"249","author":"J Song","year":"2023","unstructured":"Song J, Xiao T, Li M, Jia Q. Tumor-associated macrophages: potential therapeutic targets and diagnostic markers in cancer. Pathol Res Pract. 2023;249:154739.","journal-title":"Pathol Res Pract"},{"issue":"1","key":"6508_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1158\/0008-5472.CAN-11-2178","volume":"72","author":"H Kulbe","year":"2012","unstructured":"Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, Coward JI, Schioppa T, Robinson SC, Gallagher WM, et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012;72(1):66\u201375.","journal-title":"Cancer Res"},{"key":"6508_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1757-2215-7-19","volume":"7","author":"M Zhang","year":"2014","unstructured":"Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A, Di W. A high M1\/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res. 2014;7:19.","journal-title":"J Ovarian Res"},{"key":"6508_CR19","first-page":"97","volume":"138","author":"C Lance-Jones","year":"1988","unstructured":"Lance-Jones C. Development of neuromuscular connections: guidance of motoneuron axons to muscles in the embryonic chick hindlimb. Ciba Found Symp. 1988;138:97\u2013115.","journal-title":"Ciba Found Symp"},{"issue":"2","key":"6508_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.cyto.2012.04.020","volume":"59","author":"Y Wang","year":"2012","unstructured":"Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, Xu RC. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine. 2012;59(2):228\u201336.","journal-title":"Cytokine"},{"issue":"1","key":"6508_CR21","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-016-0542-2","volume":"15","author":"D Lane","year":"2016","unstructured":"Lane D, Matte I, Laplante C, Garde-Granger P, Carignan A, Bessette P, Rancourt C, Piche A. CCL18 from Ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling. Mol Cancer. 2016;15(1):58.","journal-title":"Mol Cancer"},{"issue":"11","key":"6508_CR22","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/mc.22419","volume":"55","author":"Q Wang","year":"2016","unstructured":"Wang Q, Tang Y, Yu H, Yin Q, Li M, Shi L, Zhang W, Li D, Li L. CCL18 from tumor-cells promotes epithelial ovarian cancer metastasis via mTOR signaling pathway. Mol Carcinog. 2016;55(11):1688\u201399.","journal-title":"Mol Carcinog"},{"issue":"9","key":"6508_CR23","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942\u20139.","journal-title":"Nat Med"},{"issue":"18","key":"6508_CR24","doi-asserted-by":"publisher","first-page":"8900","DOI":"10.1158\/0008-5472.CAN-07-1866","volume":"67","author":"I Kryczek","year":"2007","unstructured":"Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, Chen L, Coukos G, Zou W. Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res. 2007;67(18):8900\u20135.","journal-title":"Cancer Res"},{"issue":"2","key":"6508_CR25","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.4049\/jimmunol.175.2.1197","volume":"175","author":"T Hagemann","year":"2005","unstructured":"Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, Klemm F, Pukrop T, Binder C, Balkwill FR. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005;175(2):1197\u2013205.","journal-title":"J Immunol"},{"issue":"12","key":"6508_CR26","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1158\/0008-5472.CAN-06-4375","volume":"67","author":"TM Robinson-Smith","year":"2007","unstructured":"Robinson-Smith TM, Isaacsohn I, Mercer CA, Zhou M, Van Rooijen N, Husseinzadeh N, McFarland-Mancini MM, Drew AF. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res. 2007;67(12):5708\u201316.","journal-title":"Cancer Res"},{"issue":"15","key":"6508_CR27","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1093\/jnci\/94.15.1134","volume":"94","author":"S Huang","year":"2002","unstructured":"Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst. 2002;94(15):1134\u201342.","journal-title":"J Natl Cancer Inst"},{"issue":"7769","key":"6508_CR28","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41586-019-1456-0","volume":"572","author":"AA Barkal","year":"2019","unstructured":"Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, Krishnan V, Hatakeyama J, Dorigo O, Barkal LJ, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572(7769):392\u20136.","journal-title":"Nature"},{"issue":"11","key":"6508_CR29","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.1172\/JCI87252","volume":"126","author":"M Yin","year":"2016","unstructured":"Yin M, Li X, Tan S, Zhou HJ, Ji W, Bellone S, Xu X, Zhang H, Santin AD, Lou G, et al. Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer. J Clin Invest. 2016;126(11):4157\u201373.","journal-title":"J Clin Invest"},{"issue":"5","key":"6508_CR30","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1111\/cas.13567","volume":"109","author":"M Tang","year":"2018","unstructured":"Tang M, Liu B, Bu X, Zhao P. Cross-talk between ovarian cancer cells and macrophages through Periostin promotes macrophage recruitment. Cancer Sci. 2018;109(5):1309\u201318.","journal-title":"Cancer Sci"},{"issue":"2","key":"6508_CR31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ncb3090","volume":"17","author":"W Zhou","year":"2015","unstructured":"Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 2015;17(2):170\u201382.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"6508_CR32","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1084\/jem.20050930","volume":"203","author":"I Kryczek","year":"2006","unstructured":"Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med. 2006;203(4):871\u201381.","journal-title":"J Exp Med"},{"issue":"22","key":"6508_CR33","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.15252\/embj.201797345","volume":"36","author":"M Cortes","year":"2017","unstructured":"Cortes M, Sanchez-Moral L, de Barrios O, Fernandez-Acenero MJ, Martinez-Campanario MC, Esteve-Codina A, Darling DS, Gyorffy B, Lawrence T, Dean DC, et al. Tumor-associated macrophages (TAMs) depend on ZEB1 for their cancer-promoting roles. EMBO J. 2017;36(22):3336\u201355.","journal-title":"EMBO J"},{"issue":"2","key":"6508_CR34","first-page":"818","volume":"39","author":"L Liu","year":"2018","unstructured":"Liu L, Wang X, Li X, Wu X, Tang M, Wang X. Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells. Oncol Rep. 2018;39(2):818\u201326.","journal-title":"Oncol Rep"},{"issue":"1","key":"6508_CR35","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ygyno.2017.07.007","volume":"147","author":"X Yuan","year":"2017","unstructured":"Yuan X, Zhang J, Li D, Mao Y, Mo F, Du W, Ma X. Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis. Gynecol Oncol. 2017;147(1):181\u20137.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"6508_CR36","doi-asserted-by":"publisher","first-page":"e38541","DOI":"10.1371\/journal.pone.0038541","volume":"7","author":"C Le Page","year":"2012","unstructured":"Le Page C, Marineau A, Bonza PK, Rahimi K, Cyr L, Labouba I, Madore J, Delvoye N, Mes-Masson AM, Provencher DM, et al. BTN3A2 expression in epithelial ovarian cancer is associated with higher tumor infiltrating T cells and a better prognosis. PLoS ONE. 2012;7(6):e38541.","journal-title":"PLoS ONE"},{"issue":"42","key":"6508_CR37","doi-asserted-by":"publisher","first-page":"68033","DOI":"10.18632\/oncotarget.10797","volume":"7","author":"A Ciucci","year":"2016","unstructured":"Ciucci A, Zannoni GF, Buttarelli M, Martinelli E, Mascilini F, Petrillo M, Ferrandina G, Scambia G, Gallo D. Ovarian low and high grade serous carcinomas: hidden divergent features in the tumor microenvironment. Oncotarget. 2016;7(42):68033\u201343.","journal-title":"Oncotarget"},{"issue":"12","key":"6508_CR38","doi-asserted-by":"publisher","first-page":"e79769","DOI":"10.1371\/journal.pone.0079769","volume":"8","author":"YF He","year":"2013","unstructured":"He YF, Zhang MY, Wu X, Sun XJ, Xu T, He QZ, Di W. High MUC2 expression in ovarian cancer is inversely associated with the M1\/M2 ratio of tumor-associated macrophages and patient survival time. PLoS ONE. 2013;8(12):e79769.","journal-title":"PLoS ONE"},{"key":"6508_CR39","doi-asserted-by":"publisher","first-page":"101595","DOI":"10.1016\/j.smim.2022.101595","volume":"57","author":"ML De Meo","year":"2021","unstructured":"De Meo ML, Spicer JD. The role of neutrophil extracellular traps in cancer progression and metastasis. Semin Immunol. 2021;57:101595.","journal-title":"Semin Immunol"},{"issue":"9","key":"6508_CR40","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41568-020-0281-y","volume":"20","author":"S Jaillon","year":"2020","unstructured":"Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485\u2013503.","journal-title":"Nat Rev Cancer"},{"key":"6508_CR41","doi-asserted-by":"crossref","unstructured":"Quail DF, Amulic B, Aziz M, Barnes BJ, Eruslanov E, Fridlender ZG, Goodridge HS, Granot Z, Hidalgo A, Huttenlocher A et al. Neutrophil phenotypes and functions in cancer: A consensus statement. J Exp Med 2022, 219(6).","DOI":"10.1084\/jem.20220011"},{"issue":"20","key":"6508_CR42","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","volume":"133","author":"MA Giese","year":"2019","unstructured":"Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159\u201367.","journal-title":"Blood"},{"issue":"5","key":"6508_CR43","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.4049\/jimmunol.164.5.2769","volume":"164","author":"LF Lee","year":"2000","unstructured":"Lee LF, Hellendall RP, Wang Y, Haskill JS, Mukaida N, Matsushima K, Ting JP. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. J Immunol. 2000;164(5):2769\u201375.","journal-title":"J Immunol"},{"issue":"4","key":"6508_CR44","first-page":"1580","volume":"53","author":"M Yoshida","year":"2018","unstructured":"Yoshida M, Taguchi A, Kawana K, Ogishima J, Adachi K, Kawata A, Nakamura H, Sato M, Fujimoto A, Inoue T, et al. Intraperitoneal neutrophils activated by KRAS-induced ovarian cancer exert antitumor effects by modulating adaptive immunity. Int J Oncol. 2018;53(4):1580\u201390.","journal-title":"Int J Oncol"},{"issue":"15","key":"6508_CR45","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.7150\/jca.41035","volume":"11","author":"Q Liu","year":"2020","unstructured":"Liu Q, Yang W, Luo N, Liu J, Wu Y, Ding J, Li C, Cheng Z. LPS and IL-8 activated umbilical cord blood-derived neutrophils inhibit the progression of ovarian cancer. J Cancer. 2020;11(15):4413\u201320.","journal-title":"J Cancer"},{"issue":"10","key":"6508_CR46","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1172\/JCI39065","volume":"119","author":"KA Charles","year":"2009","unstructured":"Charles KA, Kulbe H, Soper R, Escorcio-Correia M, Lawrence T, Schultheis A, Chakravarty P, Thompson RG, Kollias G, Smyth JF, et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest. 2009;119(10):3011\u201323.","journal-title":"J Clin Invest"},{"issue":"2","key":"6508_CR47","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41416-018-0339-8","volume":"120","author":"KL Singel","year":"2019","unstructured":"Singel KL, Grzankowski KS, Khan A, Grimm MJ, D\u2019Auria AC, Morrell K, Eng KH, Hylander B, Mayor PC, Emmons TR, et al. Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer. Br J Cancer. 2019;120(2):207\u201317.","journal-title":"Br J Cancer"},{"issue":"3","key":"6508_CR48","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1365-3083.2008.02139.x","volume":"68","author":"M Klink","year":"2008","unstructured":"Klink M, Jastrzembska K, Nowak M, Bednarska K, Szpakowski M, Szyllo K, Sulowska Z. Ovarian cancer cells modulate human blood neutrophils response to activation in vitro. Scand J Immunol. 2008;68(3):328\u201336.","journal-title":"Scand J Immunol"},{"issue":"9","key":"6508_CR49","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1038\/s41416-020-1026-0","volume":"123","author":"M Yang","year":"2020","unstructured":"Yang M, Zhang G, Wang Y, He M, Xu Q, Lu J, Liu H, Xu C. Tumour-associated neutrophils orchestrate intratumoural IL-8-driven immune evasion through Jagged2 activation in ovarian cancer. Br J Cancer. 2020;123(9):1404\u201316.","journal-title":"Br J Cancer"},{"issue":"2","key":"6508_CR50","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/hed.27246","volume":"45","author":"X Hu","year":"2023","unstructured":"Hu X, Tian T, Zhang X, Sun Q, Chen Y, Jiang W. Neutrophil-to-lymphocyte and hypopharyngeal cancer prognosis: system review and meta-analysis. Head Neck. 2023;45(2):492\u2013502.","journal-title":"Head Neck"},{"issue":"3","key":"6508_CR51","doi-asserted-by":"publisher","first-page":"260","DOI":"10.21614\/chirurgia.2023.v.118.i.3.p.260","volume":"118","author":"CI Iaciu","year":"2023","unstructured":"Iaciu CI, Emilescu RA, Cotan HT, Nitipir C. Systemic Neutrophil-to-Lymphocyte ratio as a prognostic biomarker for Colon cancer. Chirurgia (Bucur). 2023;118(3):260\u201371.","journal-title":"Chirurgia (Bucur)"},{"issue":"2","key":"6508_CR52","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10549-022-06726-w","volume":"196","author":"Y Inoue","year":"2022","unstructured":"Inoue Y, Fujishima M, Ono M, Masuda J, Ozaki Y, Maeda T, Uehiro N, Takahashi Y, Kobayashi T, Sakai T, et al. Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer. Breast Cancer Res Treat. 2022;196(2):341\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"6508_CR53","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1007\/s00405-022-07274-1","volume":"279","author":"A Yanni","year":"2022","unstructured":"Yanni A, Buset T, Bouland C, Loeb I, Lechien JR, Rodriguez A, Journe F, Saussez S, Dequanter D. Neutrophil-to-lymphocyte ratio as a prognostic marker for head and neck cancer with lung metastasis: a retrospective study. Eur Arch Otorhinolaryngol. 2022;279(8):4103\u201311.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"2","key":"6508_CR54","doi-asserted-by":"publisher","first-page":"e000039","DOI":"10.1136\/esmoopen-2016-000039","volume":"1","author":"A Badora-Rybicka","year":"2016","unstructured":"Badora-Rybicka A, Nowara E, Starzyczny-Slota D. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. ESMO Open. 2016;1(2):e000039.","journal-title":"ESMO Open"},{"issue":"1","key":"6508_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ygyno.2018.05.004","volume":"150","author":"T Baert","year":"2018","unstructured":"Baert T, Van Camp J, Vanbrabant L, Busschaert P, Laenen A, Han S, Van Nieuwenhuysen E, Vergote I, Coosemans A. Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. Gynecol Oncol. 2018;150(1):31\u20137.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"6508_CR56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00262-008-0516-3","volume":"58","author":"H Cho","year":"2009","unstructured":"Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother. 2009;58(1):15\u201323.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"6508_CR57","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5468\/ogs.2020.63.1.55","volume":"63","author":"D Jeerakornpassawat","year":"2020","unstructured":"Jeerakornpassawat D, Suprasert P. Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy. Obstet Gynecol Sci. 2020;63(1):55\u201363.","journal-title":"Obstet Gynecol Sci"},{"issue":"1","key":"6508_CR58","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/ijgo.12986","volume":"148","author":"L Salman","year":"2020","unstructured":"Salman L, Sabah G, Jakobson-Setton A, Raban O, Yeoshoua E, Eitan R. Neutrophil-to-lymphocyte ratio as a prognostic factor in advanced stage ovarian carcinoma treated with neoadjuvant chemotherapy. Int J Gynaecol Obstet. 2020;148(1):102\u20136.","journal-title":"Int J Gynaecol Obstet"},{"key":"6508_CR59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cca.2016.03.013","volume":"456","author":"YQ Wang","year":"2016","unstructured":"Wang YQ, Jin C, Zheng HM, Zhou K, Shi BB, Zhang Q, Zheng FY, Lin F. A novel prognostic inflammation score predicts outcomes in patients with ovarian cancer. Clin Chim Acta. 2016;456:163\u20139.","journal-title":"Clin Chim Acta"},{"issue":"9","key":"6508_CR60","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1136\/ijgc-2020-001378","volume":"30","author":"JMV Nguyen","year":"2020","unstructured":"Nguyen JMV, Ferguson SE, Bernardini MQ, May T, Laframboise S, Hogen L, Bouchard-Fortier G. Preoperative neutrophil-to-lymphocyte ratio predicts 30\u00a0day postoperative morbidity and survival after primary surgery for ovarian cancer. Int J Gynecol Cancer. 2020;30(9):1378\u201383.","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"6508_CR61","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.3892\/ol.2016.4513","volume":"11","author":"K Nakamura","year":"2016","unstructured":"Nakamura K, Nagasaka T, Nishida T, Haruma T, Ogawa C, Kusumoto T, Seki N, Hiramatsu Y. Neutrophil to lymphocyte ratio in the pre-treatment phase of final-line chemotherapy predicts the outcome of patients with recurrent ovarian cancer. Oncol Lett. 2016;11(6):3975\u201381.","journal-title":"Oncol Lett"},{"issue":"16","key":"6508_CR62","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.7314\/APJCP.2014.15.16.6881","volume":"15","author":"MA Yildirim","year":"2014","unstructured":"Yildirim MA, Seckin KD, Togrul C, Baser E, Karsli MF, Gungor T, Gulerman HC. Roles of neutrophil\/lymphocyte and platelet\/lymphocyte ratios in the early diagnosis of malignant ovarian masses. Asian Pac J Cancer Prev. 2014;15(16):6881\u20135.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"6508_CR63","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, Shu P, Li D, Wang Y. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther. 2021;6(1):362.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"6508_CR64","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21(1):184.","journal-title":"Mol Cancer"},{"key":"6508_CR65","doi-asserted-by":"publisher","first-page":"949","DOI":"10.3389\/fimmu.2019.00949","volume":"10","author":"FM Consonni","year":"2019","unstructured":"Consonni FM, Porta C, Marino A, Pandolfo C, Mola S, Bleve A, Sica A. Myeloid-Derived suppressor cells: ductile targets in disease. Front Immunol. 2019;10:949.","journal-title":"Front Immunol"},{"issue":"3","key":"6508_CR66","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","volume":"37","author":"V Kumar","year":"2016","unstructured":"Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of Myeloid-Derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37(3):208\u201320.","journal-title":"Trends Immunol"},{"key":"6508_CR67","doi-asserted-by":"crossref","unstructured":"Ma T, Renz BW, Ilmer M, Koch D, Yang Y, Werner J, Bazhin AV. Myeloid-Derived suppressor cells in solid tumors. Cells 2022, 11(2).","DOI":"10.3390\/cells11020310"},{"key":"6508_CR68","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3389\/fimmu.2019.00691","volume":"10","author":"K Okla","year":"2019","unstructured":"Okla K, Czerwonka A, Wawruszak A, Bobinski M, Bilska M, Tarkowski R, Bednarek W, Wertel I, Kotarski J. Clinical relevance and immunosuppressive pattern of Circulating and infiltrating subsets of Myeloid-Derived suppressor cells (MDSCs) in epithelial ovarian Cancer. Front Immunol. 2019;10:691.","journal-title":"Front Immunol"},{"issue":"8","key":"6508_CR69","doi-asserted-by":"publisher","first-page":"e1465166","DOI":"10.1080\/2162402X.2018.1465166","volume":"7","author":"S Santegoets","year":"2018","unstructured":"Santegoets S, de Groot AF, Dijkgraaf EM, Simoes AMC, van der Noord VE, van Ham JJ, Welters MJP, Kroep JR, van der Burg SH. The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival. Oncoimmunology. 2018;7(8):e1465166.","journal-title":"Oncoimmunology"},{"issue":"44","key":"6508_CR70","doi-asserted-by":"publisher","first-page":"76843","DOI":"10.18632\/oncotarget.20164","volume":"8","author":"L Wu","year":"2017","unstructured":"Wu L, Deng Z, Peng Y, Han L, Liu J, Wang L, Li B, Zhao J, Jiao S, Wei H. Ascites-derived IL-6 and IL-10 synergistically expand CD14(+)HLA-DR(-\/low) myeloid-derived suppressor cells in ovarian cancer patients. Oncotarget. 2017;8(44):76843\u201356.","journal-title":"Oncotarget"},{"key":"6508_CR71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40425-016-0154-9","volume":"4","author":"I Montalban Del Barrio","year":"2016","unstructured":"Montalban Del Barrio I, Penski C, Schlahsa L, Stein RG, Diessner J, Wockel A, Dietl J, Lutz MB, Mittelbronn M, Wischhusen J, et al. Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape. J Immunother Cancer. 2016;4:49.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"6508_CR72","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1158\/0008-5472.CAN-17-2460","volume":"78","author":"L Li","year":"2018","unstructured":"Li L, Wang L, Li J, Fan Z, Yang L, Zhang Z, Zhang C, Yue D, Qin G, Zhang T, et al. Metformin-Induced reduction of CD39 and CD73 blocks Myeloid-Derived suppressor cell activity in patients with ovarian Cancer. Cancer Res. 2018;78(7):1779\u201391.","journal-title":"Cancer Res"},{"issue":"1","key":"6508_CR73","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.celrep.2017.09.018","volume":"21","author":"J Rodriguez-Ubreva","year":"2017","unstructured":"Rodriguez-Ubreva J, Catala-Moll F, Obermajer N, Alvarez-Errico D, Ramirez RN, Company C, Vento-Tormo R, Moreno-Bueno G, Edwards RP, Mortazavi A, et al. Prostaglandin E2 leads to the acquisition of DNMT3A-Dependent tolerogenic functions in human Myeloid-Derived suppressor cells. Cell Rep. 2017;21(1):154\u201367.","journal-title":"Cell Rep"},{"key":"6508_CR74","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.3389\/fimmu.2019.01273","volume":"10","author":"T Baert","year":"2019","unstructured":"Baert T, Vankerckhoven A, Riva M, Van Hoylandt A, Thirion G, Holger G, Mathivet T, Vergote I, Coosemans A. Myeloid derived suppressor cells: key drivers of immunosuppression in ovarian Cancer. Front Immunol. 2019;10:1273.","journal-title":"Front Immunol"},{"issue":"1","key":"6508_CR75","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/s41467-018-03966-7","volume":"9","author":"M Taki","year":"2018","unstructured":"Taki M, Abiko K, Baba T, Hamanishi J, Yamaguchi K, Murakami R, Yamanoi K, Horikawa N, Hosoe Y, Nakamura E, et al. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat Commun. 2018;9(1):1685.","journal-title":"Nat Commun"},{"issue":"12","key":"6508_CR76","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1007\/s00262-020-02628-2","volume":"69","author":"N Komura","year":"2020","unstructured":"Komura N, Mabuchi S, Shimura K, Yokoi E, Kozasa K, Kuroda H, Takahashi R, Sasano T, Kawano M, Matsumoto Y, et al. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer. Cancer Immunol Immunother. 2020;69(12):2477\u201399.","journal-title":"Cancer Immunol Immunother"},{"key":"6508_CR77","doi-asserted-by":"crossref","unstructured":"De Sanctis F, Bronte V, Ugel S. Tumor-Induced Myeloid-Derived suppressor cells. Microbiol Spectr 2016, 4(3).","DOI":"10.1128\/microbiolspec.MCHD-0016-2015"},{"key":"6508_CR78","doi-asserted-by":"crossref","unstructured":"Veglia F, Hashimoto A, Dweep H, Sanseviero E, De Leo A, Tcyganov E, Kossenkov A, Mulligan C, Nam B, Masters G et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med 2021, 218(4).","DOI":"10.1084\/jem.20201803"},{"issue":"11","key":"6508_CR79","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1158\/0008-5472.CAN-16-2238","volume":"77","author":"PS Redd","year":"2017","unstructured":"Redd PS, Ibrahim ML, Klement JD, Sharman SK, Paschall AV, Yang D, Nayak-Kapoor A, Liu K. SETD1B activates iNOS expression in Myeloid-Derived suppressor cells. Cancer Res. 2017;77(11):2834\u201343.","journal-title":"Cancer Res"},{"issue":"1","key":"6508_CR80","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41392-020-00377-3","volume":"6","author":"J Chen","year":"2021","unstructured":"Chen J, Sun HW, Yang YY, Chen HT, Yu XJ, Wu WC, Xu YT, Jin LL, Wu XJ, Xu J, et al. Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. Signal Transduct Target Ther. 2021;6(1):4.","journal-title":"Signal Transduct Target Ther"},{"key":"6508_CR81","doi-asserted-by":"crossref","unstructured":"Chen H, Yang K, Pang L, Fei J, Zhu Y, Zhou J. ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer. J Immunother Cancer 2023, 11(2).","DOI":"10.1136\/jitc-2022-005527"},{"key":"6508_CR82","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/bs.ircmb.2019.07.006","volume":"348","author":"YS Lee","year":"2019","unstructured":"Lee YS, Radford KJ. The role of dendritic cells in cancer. Int Rev Cell Mol Biol. 2019;348:123\u201378.","journal-title":"Int Rev Cell Mol Biol"},{"key":"6508_CR83","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.coi.2017.01.002","volume":"45","author":"F Veglia","year":"2017","unstructured":"Veglia F, Gabrilovich DI. Dendritic cells in cancer: the role revisited. Curr Opin Immunol. 2017;45:43\u201351.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"6508_CR84","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7\u201324.","journal-title":"Nat Rev Immunol"},{"key":"6508_CR85","doi-asserted-by":"publisher","first-page":"101481","DOI":"10.1016\/j.smim.2021.101481","volume":"52","author":"AE Marciscano","year":"2021","unstructured":"Marciscano AE, Anandasabapathy N. The role of dendritic cells in cancer and anti-tumor immunity. Semin Immunol. 2021;52:101481.","journal-title":"Semin Immunol"},{"key":"6508_CR86","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejca.2020.04.036","volume":"135","author":"B Mastelic-Gavillet","year":"2020","unstructured":"Mastelic-Gavillet B, Sarivalasis A, Lozano LE, Wyss T, Inoges S, de Vries IJM, Dartiguenave F, Jichlinski P, Derre L, Coukos G, et al. Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. Eur J Cancer. 2020;135:173\u201382.","journal-title":"Eur J Cancer"},{"issue":"22","key":"6508_CR87","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.21037\/atm-20-6388","volume":"8","author":"Y Zhai","year":"2020","unstructured":"Zhai Y, Lu Q, Lou T, Cao G, Wang S, Zhang Z. MUC16 affects the biological functions of ovarian cancer cells and induces an antitumor immune response by activating dendritic cells. Ann Transl Med. 2020;8(22):1494.","journal-title":"Ann Transl Med"},{"issue":"16","key":"6508_CR88","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1158\/0008-5472.CAN-04-1272","volume":"64","author":"TJ Curiel","year":"2004","unstructured":"Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G, et al. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res. 2004;64(16):5535\u20138.","journal-title":"Cancer Res"},{"issue":"16","key":"6508_CR89","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.1158\/0008-5472.CAN-11-0367","volume":"71","author":"SI Labidi-Galy","year":"2011","unstructured":"Labidi-Galy SI, Sisirak V, Meeus P, Gobert M, Treilleux I, Bajard A, Combes JD, Faget J, Mithieux F, Cassignol A, et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 2011;71(16):5423\u201334.","journal-title":"Cancer Res"},{"issue":"20","key":"6508_CR90","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1158\/0008-5472.CAN-12-2271","volume":"72","author":"C Conrad","year":"2012","unstructured":"Conrad C, Gregorio J, Wang YH, Ito T, Meller S, Hanabuchi S, Anderson S, Atkinson N, Ramirez PT, Liu YJ, et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res. 2012;72(20):5240\u20139.","journal-title":"Cancer Res"},{"issue":"12","key":"6508_CR91","doi-asserted-by":"publisher","first-page":"5020","DOI":"10.1158\/0008-5472.CAN-04-4043","volume":"65","author":"S Wei","year":"2005","unstructured":"Wei S, Kryczek I, Zou L, Daniel B, Cheng P, Mottram P, Curiel T, Lange A, Zou W. Plasmacytoid dendritic cells induce CD8\u2009+\u2009regulatory T cells in human ovarian carcinoma. Cancer Res. 2005;65(12):5020\u20136.","journal-title":"Cancer Res"},{"issue":"3","key":"6508_CR92","doi-asserted-by":"publisher","first-page":"380","DOI":"10.4161\/onci.18801","volume":"1","author":"SI Labidi-Galy","year":"2012","unstructured":"Labidi-Galy SI, Treilleux I, Goddard-Leon S, Combes JD, Blay JY, Ray-Coquard I, Caux C, Bendriss-Vermare N. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology. 2012;1(3):380\u20132.","journal-title":"Oncoimmunology"},{"issue":"18","key":"6508_CR93","doi-asserted-by":"publisher","first-page":"7684","DOI":"10.1158\/0008-5472.CAN-08-1167","volume":"68","author":"E Huarte","year":"2008","unstructured":"Huarte E, Cubillos-Ruiz JR, Nesbeth YC, Scarlett UK, Martinez DG, Buckanovich RJ, Benencia F, Stan RV, Keler T, Sarobe P, et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res. 2008;68(18):7684\u201391.","journal-title":"Cancer Res"},{"issue":"7","key":"6508_CR94","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.cell.2015.05.025","volume":"161","author":"JR Cubillos-Ruiz","year":"2015","unstructured":"Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, Song M, Zhang S, Bettigole SE, Gupta D, Holcomb K, et al. ER stress sensor XBP1 controls Anti-tumor immunity by disrupting dendritic cell homeostasis. Cell. 2015;161(7):1527\u201338.","journal-title":"Cell"},{"issue":"1","key":"6508_CR95","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s40425-018-0446-3","volume":"6","author":"I Truxova","year":"2018","unstructured":"Truxova I, Kasikova L, Hensler M, Skapa P, Laco J, Pecen L, Belicova L, Praznovec I, Halaska MJ, Brtnicky T, et al. Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. J Immunother Cancer. 2018;6(1):139.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"6508_CR96","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/nm863","volume":"9","author":"TJ Curiel","year":"2003","unstructured":"Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9(5):562\u20137.","journal-title":"Nat Med"},{"issue":"4","key":"6508_CR97","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1172\/JCI120803","volume":"128","author":"H Lin","year":"2018","unstructured":"Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest. 2018;128(4):1708.","journal-title":"J Clin Invest"},{"issue":"20","key":"6508_CR98","doi-asserted-by":"publisher","first-page":"5498","DOI":"10.1182\/blood-2011-07-365825","volume":"118","author":"N Obermajer","year":"2011","unstructured":"Obermajer N, Muthuswamy R, Lesnock J, Edwards RP, Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood. 2011;118(20):5498\u2013505.","journal-title":"Blood"},{"issue":"1","key":"6508_CR99","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1038\/s41467-020-18962-z","volume":"11","author":"MS Block","year":"2020","unstructured":"Block MS, Dietz AB, Gustafson MP, Kalli KR, Erskine CL, Youssef B, Vijay GV, Allred JB, Pavelko KD, Strausbauch MA, et al. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. Nat Commun. 2020;11(1):5173.","journal-title":"Nat Commun"},{"issue":"4","key":"6508_CR100","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1517\/14712598.2011.554812","volume":"11","author":"MJ Cannon","year":"2011","unstructured":"Cannon MJ, Goyne H, Stone PJ, Chiriva-Internati M. Dendritic cell vaccination against ovarian cancer\u2013tipping the Treg\/TH17 balance to therapeutic advantage? Expert Opin Biol Ther. 2011;11(4):441\u20135.","journal-title":"Expert Opin Biol Ther"},{"key":"6508_CR101","doi-asserted-by":"crossref","unstructured":"Luo Y, Shreeder B, Jenkins JW, Shi H, Lamichhane P, Zhou K, Bahr DA, Kurian S, Jones KA, Daum JI et al. Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint Blockade. J Immunother Cancer 2023, 11(11).","DOI":"10.1136\/jitc-2023-007661"},{"issue":"17","key":"6508_CR102","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-13-1185","volume":"19","author":"CL Chiang","year":"2013","unstructured":"Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, Montone K, Mantia-Smaldone GM, Smith L, Nisenbaum HL, et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res. 2013;19(17):4801\u201315.","journal-title":"Clin Cancer Res"},{"key":"6508_CR103","doi-asserted-by":"crossref","unstructured":"Portale F, Di Mitri D. NK cells in cancer: mechanisms of dysfunction and therapeutic potential. Int J Mol Sci 2023, 24(11).","DOI":"10.3390\/ijms24119521"},{"issue":"1","key":"6508_CR104","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","volume":"19","author":"SY Wu","year":"2020","unstructured":"Wu SY, Fu T, Jiang YZ, Shao ZM. Natural killer cells in cancer biology and therapy. Mol Cancer. 2020;19(1):120.","journal-title":"Mol Cancer"},{"issue":"3","key":"6508_CR105","doi-asserted-by":"publisher","first-page":"1557030","DOI":"10.1080\/2162402X.2018.1557030","volume":"8","author":"FR Mariotti","year":"2019","unstructured":"Mariotti FR, Petrini S, Ingegnere T, Tumino N, Besi F, Scordamaglia F, Munari E, Pesce S, Marcenaro E, Moretta A, et al. PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression. Oncoimmunology. 2019;8(3):1557030.","journal-title":"Oncoimmunology"},{"issue":"1","key":"6508_CR106","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","volume":"139","author":"S Pesce","year":"2017","unstructured":"Pesce S, Greppi M, Tabellini G, Rampinelli F, Parolini S, Olive D, Moretta L, Moretta A, Marcenaro E. Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization. J Allergy Clin Immunol. 2017;139(1):335\u2013e346333.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"6508_CR107","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00262-008-0585-3","volume":"58","author":"K Li","year":"2009","unstructured":"Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S, Konishi I. Clinical significance of the NKG2D ligands, MICA\/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother. 2009;58(5):641\u201352.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"6508_CR108","doi-asserted-by":"publisher","first-page":"e13284","DOI":"10.1111\/aji.13284","volume":"84","author":"J Vazquez","year":"2020","unstructured":"Vazquez J, Chavarria M, Lopez GE, Felder MA, Kapur A, Romo Chavez A, Karst N, Barroilhet L, Patankar MS, Stanic AK. Identification of unique clusters of T, dendritic, and innate lymphoid cells in the peritoneal fluid of ovarian cancer patients. Am J Reprod Immunol. 2020;84(3):e13284.","journal-title":"Am J Reprod Immunol"},{"issue":"3","key":"6508_CR109","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1309\/15B66DQMFYYM78CJ","volume":"125","author":"HP Dong","year":"2006","unstructured":"Dong HP, Elstrand MB, Holth A, Silins I, Berner A, Trope CG, Davidson B, Risberg B. NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. Am J Clin Pathol. 2006;125(3):451\u20138.","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"6508_CR110","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1158\/1078-0432.CCR-13-1877","volume":"20","author":"JR Webb","year":"2014","unstructured":"Webb JR, Milne K, Watson P, Deleeuw RJ, Nelson BH. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res. 2014;20(2):434\u201344.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"6508_CR111","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1080\/0284186X.2019.1711173","volume":"59","author":"JR Henriksen","year":"2020","unstructured":"Henriksen JR, Donskov F, Waldstrom M, Jakobsen A, Hjortkjaer M, Petersen CB, Dahl Steffensen K. Favorable prognostic impact of natural killer cells and T cells in high-grade serous ovarian carcinoma. Acta Oncol. 2020;59(6):652\u20139.","journal-title":"Acta Oncol"},{"issue":"11","key":"6508_CR112","doi-asserted-by":"publisher","first-page":"7338","DOI":"10.4049\/jimmunol.180.11.7338","volume":"180","author":"M Krockenberger","year":"2008","unstructured":"Krockenberger M, Dombrowski Y, Weidler C, Ossadnik M, Honig A, Hausler S, Voigt H, Becker JC, Leng L, Steinle A, et al. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NKG2D. J Immunol. 2008;180(11):7338\u201348.","journal-title":"J Immunol"},{"issue":"2","key":"6508_CR113","doi-asserted-by":"publisher","first-page":"101425","DOI":"10.1016\/j.xpro.2022.101425","volume":"3","author":"A Delgado-Gonzalez","year":"2022","unstructured":"Delgado-Gonzalez A, Huang YW, Porpiglia E, Donoso K, Gonzalez VD, Fantl WJ. Measuring trogocytosis between ovarian tumor and natural killer cells. STAR Protoc. 2022;3(2):101425.","journal-title":"STAR Protoc"},{"issue":"4","key":"6508_CR114","doi-asserted-by":"publisher","first-page":"e1001224","DOI":"10.1080\/2162402X.2014.1001224","volume":"4","author":"S Pesce","year":"2015","unstructured":"Pesce S, Tabellini G, Cantoni C, Patrizi O, Coltrini D, Rampinelli F, Matta J, Vivier E, Moretta A, Parolini S, et al. B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology. 2015;4(4):e1001224.","journal-title":"Oncoimmunology"},{"issue":"8","key":"6508_CR115","first-page":"9428","volume":"8","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Xu Y, Chen L, Xu B, Wu C, Jiang J. B7-H6 expression correlates with cancer progression and patient\u2019s survival in human ovarian cancer. Int J Clin Exp Pathol. 2015;8(8):9428\u201333.","journal-title":"Int J Clin Exp Pathol"},{"issue":"78","key":"6508_CR116","doi-asserted-by":"publisher","first-page":"34810","DOI":"10.18632\/oncotarget.26199","volume":"9","author":"JS Hoogstad-van Evert","year":"2018","unstructured":"Hoogstad-van Evert JS, Maas RJ, van der Meer J, Cany J, van der Steen S, Jansen JH, Miller JS, Bekkers R, Hobo W, Massuger L, et al. Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients. Oncotarget. 2018;9(78):34810\u201320.","journal-title":"Oncotarget"},{"issue":"9","key":"6508_CR117","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12032-022-01735-7","volume":"39","author":"K Mortezaee","year":"2022","unstructured":"Mortezaee K, Majidpoor J. NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives. Med Oncol. 2022;39(9):131.","journal-title":"Med Oncol"},{"issue":"2","key":"6508_CR118","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18(2):85\u2013100.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"6508_CR119","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19(3):200\u201318.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"6508_CR120","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00262-017-2112-x","volume":"67","author":"T Nham","year":"2018","unstructured":"Nham T, Poznanski SM, Fan IY, Shenouda MM, Chew MV, Lee AJ, Vahedi F, Karimi Y, Butcher M, Lee DA, et al. Ex vivo-expanded NK cells from blood and Ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells. Cancer Immunol Immunother. 2018;67(4):575\u201387.","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"6508_CR121","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.ccell.2021.04.004","volume":"39","author":"M Hornburg","year":"2021","unstructured":"Hornburg M, Desbois M, Lu S, Guan Y, Lo AA, Kaufman S, Elrod A, Lotstein A, DesRochers TM, Munoz-Rodriguez JL, et al. Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell. 2021;39(7):928\u2013e944926.","journal-title":"Cancer Cell"},{"issue":"2","key":"6508_CR122","doi-asserted-by":"publisher","first-page":"e1535730","DOI":"10.1080\/2162402X.2018.1535730","volume":"8","author":"E Radestad","year":"2019","unstructured":"Radestad E, Klynning C, Stikvoort A, Mogensen O, Nava S, Magalhaes I, Uhlin M. Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer. Oncoimmunology. 2019;8(2):e1535730.","journal-title":"Oncoimmunology"},{"issue":"4","key":"6508_CR123","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1093\/annonc\/mdi112","volume":"16","author":"MR Raspollini","year":"2005","unstructured":"Raspollini MR, Castiglione F, Rossi Degl\u2019innocenti D, Amunni G, Villanucci A, Garbini F, Baroni G, Taddei GL. Tumour-infiltrating gamma\/delta T-lymphocytes are correlated with a brief disease-free interval in advanced ovarian serous carcinoma. Ann Oncol. 2005;16(4):590\u20136.","journal-title":"Ann Oncol"},{"issue":"46","key":"6508_CR124","doi-asserted-by":"publisher","first-page":"75130","DOI":"10.18632\/oncotarget.12077","volume":"7","author":"FL Komdeur","year":"2016","unstructured":"Komdeur FL, Wouters MC, Workel HH, Tijans AM, Terwindt AL, Brunekreeft KL, Plat A, Klip HG, Eggink FA, Leffers N, et al. CD103\u2009+\u2009intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRalphabeta\u2009+\u2009CD8alphabeta\u2009+\u2009T cells that can be targeted for cancer immunotherapy. Oncotarget. 2016;7(46):75130\u201344.","journal-title":"Oncotarget"},{"issue":"3","key":"6508_CR125","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/modpathol.2008.187","volume":"22","author":"M Liu","year":"2009","unstructured":"Liu M, Matsumura N, Mandai M, Li K, Yagi H, Baba T, Suzuki A, Hamanishi J, Fukuhara K, Konishi I. Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression. Mod Pathol. 2009;22(3):373\u201384.","journal-title":"Mod Pathol"},{"issue":"11","key":"6508_CR126","doi-asserted-by":"publisher","first-page":"e80063","DOI":"10.1371\/journal.pone.0080063","volume":"8","author":"CC Preston","year":"2013","unstructured":"Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL. The ratios of CD8\u2009+\u2009T cells to CD4\u2009+\u2009CD25\u2009+\u2009FOXP3\u2009+\u2009and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS ONE. 2013;8(11):e80063.","journal-title":"PLoS ONE"},{"issue":"5","key":"6508_CR127","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/ijc.27759","volume":"132","author":"A Fialova","year":"2013","unstructured":"Fialova A, Partlova S, Sojka L, Hromadkova H, Brtnicky T, Fucikova J, Kocian P, Rob L, Bartunkova J, Spisek R. Dynamics of T-cell infiltration during the course of ovarian cancer: the gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T-cells. Int J Cancer. 2013;132(5):1070\u20139.","journal-title":"Int J Cancer"},{"issue":"3","key":"6508_CR128","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/modpathol.2008.191","volume":"22","author":"B Clarke","year":"2009","unstructured":"Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, Kalloger S, Han G, Ceballos K, Cadungog MG, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22(3):393\u2013402.","journal-title":"Mod Pathol"},{"issue":"2","key":"6508_CR129","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1006\/cimm.1996.0301","volume":"174","author":"S Kooi","year":"1996","unstructured":"Kooi S, Zhang HZ, Patenia R, Edwards CL, Platsoucas CD, Freedman RS. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of Recombinant interleukin-2. Cell Immunol. 1996;174(2):116\u201328.","journal-title":"Cell Immunol"},{"issue":"3","key":"6508_CR130","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00262-008-0583-5","volume":"58","author":"N Leffers","year":"2009","unstructured":"Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2009;58(3):449\u201359.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"6508_CR131","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203\u201313.","journal-title":"N Engl J Med"},{"issue":"8","key":"6508_CR132","first-page":"2875","volume":"29","author":"RL Giuntoli","year":"2009","unstructured":"Giuntoli RL 2nd, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M. Ovarian cancer-associated Ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res. 2009;29(8):2875\u201384.","journal-title":"Anticancer Res"},{"key":"6508_CR133","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/1471-2407-11-210","volume":"11","author":"D Lane","year":"2011","unstructured":"Lane D, Matte I, Rancourt C, Piche A. Prognostic significance of IL-6 and IL-8 Ascites levels in ovarian cancer patients. BMC Cancer. 2011;11:210.","journal-title":"BMC Cancer"},{"issue":"3","key":"6508_CR134","doi-asserted-by":"publisher","first-page":"e1090075","DOI":"10.1080\/2162402X.2015.1090075","volume":"5","author":"DK Chang","year":"2016","unstructured":"Chang DK, Peterson E, Sun J, Goudie C, Drapkin RI, Liu JF, Matulonis U, Zhu Q, Marasco WA. Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016;5(3):e1090075.","journal-title":"Oncoimmunology"},{"key":"6508_CR135","doi-asserted-by":"publisher","first-page":"175883592096724","DOI":"10.1177\/1758835920967241","volume":"12","author":"J Hao","year":"2020","unstructured":"Hao J, Yu H, Zhang T, An R, Xue Y. Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920967241.","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"6508_CR136","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.trecan.2023.07.015","volume":"9","author":"JH Kang","year":"2023","unstructured":"Kang JH, Zappasodi R. Modulating Treg stability to improve cancer immunotherapy. Trends Cancer. 2023;9(11):911\u201327.","journal-title":"Trends Cancer"},{"key":"6508_CR137","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3389\/fimmu.2020.00676","volume":"11","author":"M Xie","year":"2020","unstructured":"Xie M, Wei J, Xu J. Inducers, attractors and modulators of CD4(+) Treg cells in Non-Small-Cell lung Cancer. Front Immunol. 2020;11:676.","journal-title":"Front Immunol"},{"issue":"3","key":"6508_CR138","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00262-014-1636-6","volume":"64","author":"J Landskron","year":"2015","unstructured":"Landskron J, Helland O, Torgersen KM, Aandahl EM, Gjertsen BT, Bjorge L, Tasken K. Activated regulatory and memory T-cells accumulate in malignant Ascites from ovarian carcinoma patients. Cancer Immunol Immunother. 2015;64(3):337\u201347.","journal-title":"Cancer Immunol Immunother"},{"issue":"12","key":"6508_CR139","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1158\/0008-5472.CAN-05-0141","volume":"65","author":"S Sharma","year":"2005","unstructured":"Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM. Tumor cyclooxygenase-2\/prostaglandin E2-dependent promotion of FOXP3 expression and CD4\u2009+\u2009CD25\u2009+\u2009T regulatory cell activities in lung cancer. Cancer Res. 2005;65(12):5211\u201320.","journal-title":"Cancer Res"},{"issue":"4","key":"6508_CR140","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.semcancer.2012.03.004","volume":"22","author":"TL Whiteside","year":"2012","unstructured":"Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol. 2012;22(4):327\u201334.","journal-title":"Semin Cancer Biol"},{"issue":"7355","key":"6508_CR141","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10169","volume":"475","author":"A Facciabene","year":"2011","unstructured":"Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature. 2011;475(7355):226\u201330.","journal-title":"Nature"},{"key":"6508_CR142","doi-asserted-by":"crossref","unstructured":"Cassar E, Kartikasari AER, Plebanski M. Regulatory T Cells in Ovarian Carcinogenesis and Future Therapeutic Opportunities. Cancers (Basel) 2022, 14(22).","DOI":"10.3390\/cancers14225488"},{"issue":"12","key":"6508_CR143","first-page":"4766","volume":"61","author":"EY Woo","year":"2001","unstructured":"Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001;61(12):4766\u201372.","journal-title":"Cancer Res"},{"issue":"11","key":"6508_CR144","doi-asserted-by":"publisher","first-page":"e111757","DOI":"10.1371\/journal.pone.0111757","volume":"9","author":"C Hermans","year":"2014","unstructured":"Hermans C, Anz D, Engel J, Kirchner T, Endres S, Mayr D. Analysis of FoxP3\u2009+\u2009T-regulatory cells and CD8\u2009+\u2009T-cells in ovarian carcinoma: location and tumor infiltration patterns are key prognostic markers. PLoS ONE. 2014;9(11):e111757.","journal-title":"PLoS ONE"},{"key":"6508_CR145","doi-asserted-by":"publisher","first-page":"345164","DOI":"10.1155\/2012\/345164","volume":"2012","author":"DJ Peng","year":"2012","unstructured":"Peng DJ, Liu R, Zou W. Regulatory T cells in human ovarian cancer. J Oncol. 2012;2012:345164.","journal-title":"J Oncol"},{"issue":"3","key":"6508_CR146","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1600-0897.2011.01068.x","volume":"67","author":"AB Alvero","year":"2012","unstructured":"Alvero AB, Montagna MK, Craveiro V, Liu L, Mor G. Distinct subpopulations of epithelial ovarian cancer cells can differentially induce macrophages and T regulatory cells toward a pro-tumor phenotype. Am J Reprod Immunol. 2012;67(3):256\u201365.","journal-title":"Am J Reprod Immunol"},{"issue":"1","key":"6508_CR147","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41591-018-0266-5","volume":"25","author":"W Scheper","year":"2019","unstructured":"Scheper W, Kelderman S, Fanchi LF, Linnemann C, Bendle G, de Rooij MAJ, Hirt C, Mezzadra R, Slagter M, Dijkstra K, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med. 2019;25(1):89\u201394.","journal-title":"Nat Med"},{"issue":"7637","key":"6508_CR148","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"29","key":"6508_CR149","doi-asserted-by":"publisher","first-page":"27359","DOI":"10.18632\/oncotarget.4751","volume":"6","author":"RY Huang","year":"2015","unstructured":"Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8\u2009+\u2009T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015;6(29):27359\u201377.","journal-title":"Oncotarget"},{"key":"6508_CR150","doi-asserted-by":"crossref","unstructured":"Gavalas NG, Karadimou A, Dimopoulos MA, Bamias A. Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. Clin Dev Immunol 2010, 2010:791603.","DOI":"10.1155\/2010\/791603"},{"issue":"10","key":"6508_CR151","doi-asserted-by":"publisher","first-page":"e46858","DOI":"10.1371\/journal.pone.0046858","volume":"7","author":"A Latifi","year":"2012","unstructured":"Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK, et al. Isolation and characterization of tumor cells from the Ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PLoS ONE. 2012;7(10):e46858.","journal-title":"PLoS ONE"},{"issue":"8","key":"6508_CR152","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","volume":"21","author":"D Briukhovetska","year":"2021","unstructured":"Briukhovetska D, Dorr J, Endres S, Libby P, Dinarello CA, Kobold S. Interleukins in cancer: from biology to therapy. Nat Rev Cancer. 2021;21(8):481\u201399.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"6508_CR153","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41577-018-0066-7","volume":"18","author":"SA Jones","year":"2018","unstructured":"Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol. 2018;18(12):773\u201389.","journal-title":"Nat Rev Immunol"},{"key":"6508_CR154","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.3389\/fimmu.2017.01482","volume":"8","author":"NC Kampan","year":"2017","unstructured":"Kampan NC, Madondo MT, McNally OM, Stephens AN, Quinn MA, Plebanski M. Interleukin 6 present in inflammatory Ascites from advanced epithelial ovarian Cancer patients promotes tumor necrosis factor receptor 2-Expressing regulatory T cells. Front Immunol. 2017;8:1482.","journal-title":"Front Immunol"},{"issue":"5","key":"6508_CR155","first-page":"566","volume":"2","author":"I Matte","year":"2012","unstructured":"Matte I, Lane D, Laplante C, Rancourt C, Piche A. Profiling of cytokines in human epithelial ovarian cancer Ascites. Am J Cancer Res. 2012;2(5):566\u201380.","journal-title":"Am J Cancer Res"},{"issue":"4","key":"6508_CR156","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.immuni.2019.03.020","volume":"50","author":"W Ouyang","year":"2019","unstructured":"Ouyang W, O\u2019Garra A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity. 2019;50(4):871\u201391.","journal-title":"Immunity"},{"key":"6508_CR157","doi-asserted-by":"crossref","unstructured":"Chehade H, Tedja R, Ramos H, Bawa TS, Adzibolosu N, Gogoi R, Mor G, Alvero AB. Regulatory role of the adipose microenvironment on ovarian Cancer progression. Cancers (Basel) 2022, 14(9).","DOI":"10.3390\/cancers14092267"},{"issue":"1","key":"6508_CR158","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13048-020-00718-4","volume":"13","author":"L Dai","year":"2020","unstructured":"Dai L, Song K, Di W. Adipocytes: active facilitators in epithelial ovarian cancer progression? J Ovarian Res. 2020;13(1):115.","journal-title":"J Ovarian Res"},{"key":"6508_CR159","doi-asserted-by":"crossref","unstructured":"Duarte Mendes A, Freitas AR, Vicente R, Vitorino M, Vaz Batista M, Silva M, Braga S. Adipocyte microenvironment in ovarian cancer: A critical contributor?? Int J Mol Sci 2023, 24(23).","DOI":"10.3390\/ijms242316589"},{"issue":"4","key":"6508_CR160","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4274\/jtgga.galenos.2019.2018.0165","volume":"20","author":"JD Spiliotis","year":"2019","unstructured":"Spiliotis JD, Iavazzo C, Kopanakis ND, Christopoulou A. Secondary debulking for ovarian carcinoma relapse: the R-R dilemma - is the prognosis different for residual or recurrent disease? J Turk Ger Gynecol Assoc. 2019;20(4):213\u20137.","journal-title":"J Turk Ger Gynecol Assoc"},{"issue":"1","key":"6508_CR161","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ygyno.2020.12.033","volume":"161","author":"M Bilbao","year":"2021","unstructured":"Bilbao M, Aikins JK, Ostrovsky O. Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications. Gynecol Oncol. 2021;161(1):78\u201382.","journal-title":"Gynecol Oncol"},{"key":"6508_CR162","doi-asserted-by":"crossref","unstructured":"Yao H, He S. Multi\u2013faceted role of cancer\u2013associated adipocytes in the tumor microenvironment (Review). Mol Med Rep 2021, 24(6).","DOI":"10.3892\/mmr.2021.12506"},{"issue":"11","key":"6508_CR163","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/nm.2492","volume":"17","author":"KM Nieman","year":"2011","unstructured":"Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498\u2013503.","journal-title":"Nat Med"},{"issue":"1","key":"6508_CR164","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.cyto.2012.04.013","volume":"59","author":"Y Wang","year":"2012","unstructured":"Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ, Meng XY. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. Cytokine. 2012;59(1):145\u201355.","journal-title":"Cytokine"},{"key":"6508_CR165","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.semcancer.2018.10.002","volume":"53","author":"N Ahmed","year":"2018","unstructured":"Ahmed N, Escalona R, Leung D, Chan E, Kannourakis G. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells. Semin Cancer Biol. 2018;53:265\u201381.","journal-title":"Semin Cancer Biol"},{"issue":"11","key":"6508_CR166","doi-asserted-by":"publisher","first-page":"e11487","DOI":"10.1016\/j.heliyon.2022.e11487","volume":"8","author":"H Kobayashi","year":"2022","unstructured":"Kobayashi H. Recent advances in Understanding the metabolic plasticity of ovarian cancer: A systematic review. Heliyon. 2022;8(11):e11487.","journal-title":"Heliyon"},{"issue":"3","key":"6508_CR167","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3892\/br.2017.955","volume":"7","author":"H Kobayashi","year":"2017","unstructured":"Kobayashi H, Iwai K, Niiro E, Morioka S, Yamada Y, Ogawa K, Kawahara N. The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer. Biomed Rep. 2017;7(3):209\u201313.","journal-title":"Biomed Rep"},{"issue":"2","key":"6508_CR168","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ccell.2016.06.020","volume":"30","author":"F Miranda","year":"2016","unstructured":"Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, et al. Salt-Inducible kinase 2 couples ovarian Cancer cell metabolism with survival at the Adipocyte-Rich metastatic niche. Cancer Cell. 2016;30(2):273\u201389.","journal-title":"Cancer Cell"},{"issue":"1","key":"6508_CR169","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00262-019-02445-2","volume":"69","author":"C Yu","year":"2020","unstructured":"Yu C, Niu X, Du Y, Chen Y, Liu X, Xu L, Iwakura Y, Ma X, Li Y, Yao Z, et al. IL-17A promotes fatty acid uptake through the IL-17A\/IL-17RA\/p-STAT3\/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment. Cancer Immunol Immunother. 2020;69(1):115\u201326.","journal-title":"Cancer Immunol Immunother"},{"issue":"22","key":"6508_CR170","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1038\/s41388-019-0728-3","volume":"38","author":"B John","year":"2019","unstructured":"John B, Naczki C, Patel C, Ghoneum A, Qasem S, Salih Z, Said N. Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC. Oncogene. 2019;38(22):4366\u201383.","journal-title":"Oncogene"},{"key":"6508_CR171","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cellsig.2017.01.020","volume":"32","author":"A Ghasemi","year":"2017","unstructured":"Ghasemi A, Hashemy SI, Aghaei M, Panjehpour M. RhoA\/ROCK pathway mediates leptin-induced uPA expression to promote cell invasion in ovarian cancer cells. Cell Signal. 2017;32:104\u201314.","journal-title":"Cell Signal"},{"issue":"55","key":"6508_CR172","doi-asserted-by":"publisher","first-page":"93530","DOI":"10.18632\/oncotarget.19873","volume":"8","author":"J Kumar","year":"2017","unstructured":"Kumar J, Fang H, McCulloch DR, Crowley T, Ward AC. Leptin receptor signaling via Janus kinase 2\/signal transducer and activator of transcription 3 impacts on ovarian cancer cell phenotypes. Oncotarget. 2017;8(55):93530\u201340.","journal-title":"Oncotarget"},{"key":"6508_CR173","doi-asserted-by":"crossref","unstructured":"Assidi M, Yahya FM, Al-Zahrani MH, Elkhatib R, Zari A, Elaimi A, Al-Maghrabi J, Dallol A, Buhmeida A, Abu-Elmagd M. Leptin protein expression and promoter methylation in ovarian cancer: A strong prognostic value with theranostic promises. Int J Mol Sci 2021, 22(23).","DOI":"10.3390\/ijms222312872"},{"issue":"25","key":"6508_CR174","doi-asserted-by":"publisher","first-page":"21100","DOI":"10.18632\/oncotarget.4228","volume":"6","author":"S Kato","year":"2015","unstructured":"Kato S, Abarzua-Catalan L, Trigo C, Delpiano A, Sanhueza C, Garcia K, Ibanez C, Hormazabal K, Diaz D, Branes J, et al. Leptin stimulates migration and invasion and maintains cancer stem-like properties in ovarian cancer cells: an explanation for poor outcomes in obese women. Oncotarget. 2015;6(25):21100\u201319.","journal-title":"Oncotarget"},{"issue":"5","key":"6508_CR175","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nri1350","volume":"4","author":"A La Cava","year":"2004","unstructured":"La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004;4(5):371\u20139.","journal-title":"Nat Rev Immunol"},{"key":"6508_CR176","doi-asserted-by":"publisher","first-page":"585887","DOI":"10.3389\/fendo.2021.585887","volume":"12","author":"M Obradovic","year":"2021","unstructured":"Obradovic M, Sudar-Milovanovic E, Soskic S, Essack M, Arya S, Stewart AJ, Gojobori T, Isenovic ER. Leptin and obesity: role and clinical implication. Front Endocrinol (Lausanne). 2021;12:585887.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"6508_CR177","first-page":"561","volume":"18","author":"F Gu","year":"2019","unstructured":"Gu F, Zhang H, Yao L, Jiang S, Lu H, Xing X, Zhang C, Jiang P, Zhang R. Leptin contributes to the taxol chemoresistance in epithelial ovarian cancer. Oncol Lett. 2019;18(1):561\u201370.","journal-title":"Oncol Lett"},{"issue":"3","key":"6508_CR178","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3892\/ijo.2013.1789","volume":"42","author":"C Chen","year":"2013","unstructured":"Chen C, Chang YC, Lan MS, Breslin M. Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing Cyclin D1 and Mcl-1 expression via the activation of the MEK\/ERK1\/2 and PI3K\/Akt signaling pathways. Int J Oncol. 2013;42(3):1113\u20139.","journal-title":"Int J Oncol"},{"key":"6508_CR179","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3389\/fonc.2019.00778","volume":"9","author":"A Santoro","year":"2019","unstructured":"Santoro A, Angelico G, Piermattei A, Inzani F, Valente M, Arciuolo D, Spadola S, Mule A, Zorzato P, Fagotti A, et al. Pathological chemotherapy response score in patients affected by high grade serous ovarian carcinoma: the prognostic role of omental and ovarian residual disease. Front Oncol. 2019;9:778.","journal-title":"Front Oncol"},{"issue":"5","key":"6508_CR180","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s10147-021-01866-3","volume":"26","author":"Y Iwagoi","year":"2021","unstructured":"Iwagoi Y, Motohara T, Hwang S, Fujimoto K, Ikeda T, Katabuchi H. Omental metastasis as a predictive risk factor for unfavorable prognosis in patients with stage III-IV epithelial ovarian cancer. Int J Clin Oncol. 2021;26(5):995\u20131004.","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"6508_CR181","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s10495-016-1339-x","volume":"22","author":"C Cardenas","year":"2017","unstructured":"Cardenas C, Montagna MK, Pitruzzello M, Lima E, Mor G, Alvero AB. Adipocyte microenvironment promotes Bcl(xl) expression and confers chemoresistance in ovarian cancer cells. Apoptosis. 2017;22(4):558\u201369.","journal-title":"Apoptosis"},{"issue":"8","key":"6508_CR182","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1158\/0008-5472.CAN-19-1999","volume":"80","author":"A Mukherjee","year":"2020","unstructured":"Mukherjee A, Chiang CY, Daifotis HA, Nieman KM, Fahrmann JF, Lastra RR, Romero IL, Fiehn O, Lengyel E. Adipocyte-Induced FABP4 expression in ovarian Cancer cells promotes metastasis and mediates carboplatin resistance. Cancer Res. 2020;80(8):1748\u201361.","journal-title":"Cancer Res"},{"key":"6508_CR183","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.phrs.2016.01.001","volume":"106","author":"L Amable","year":"2016","unstructured":"Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27\u201336.","journal-title":"Pharmacol Res"},{"issue":"5","key":"6508_CR184","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1172\/JCI23424","volume":"115","author":"P Iyengar","year":"2005","unstructured":"Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, Lee H, Temple K, Graves R, Pollard J, et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor\/stroma microenvironment. J Clin Invest. 2005;115(5):1163\u201376.","journal-title":"J Clin Invest"},{"issue":"4","key":"6508_CR185","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1535-6108(03)00058-8","volume":"3","author":"CA Sherman-Baust","year":"2003","unstructured":"Sherman-Baust CA, Weeraratna AT, Rangel LB, Pizer ES, Cho KR, Schwartz DR, Shock T, Morin PJ. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell. 2003;3(4):377\u201386.","journal-title":"Cancer Cell"},{"issue":"1","key":"6508_CR186","doi-asserted-by":"publisher","first-page":"13316","DOI":"10.1038\/s41598-019-49649-1","volume":"9","author":"J Yang","year":"2019","unstructured":"Yang J, Zaman MM, Vlasakov I, Roy R, Huang L, Martin CR, Freedman SD, Serhan CN, Moses MA. Adipocytes promote ovarian cancer chemoresistance. Sci Rep. 2019;9(1):13316.","journal-title":"Sci Rep"},{"issue":"12","key":"6508_CR187","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18(12):792\u2013804.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"6508_CR188","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","volume":"6","author":"F Wu","year":"2021","unstructured":"Wu F, Yang J, Liu J, Wang Y, Mu J, Zeng Q, Deng S, Zhou H. Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer. Signal Transduct Target Ther. 2021;6(1):218.","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"6508_CR189","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nri2808","volume":"10","author":"RA Flavell","year":"2010","unstructured":"Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Limon P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol. 2010;10(8):554\u201367.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"6508_CR190","doi-asserted-by":"publisher","first-page":"373","DOI":"10.32604\/or.2023.031404","volume":"32","author":"J Wu","year":"2023","unstructured":"Wu J, Liao Q, Zhang LI, Wu S, Liu Z. TGF-beta-regulated different iron metabolism processes in the development and cisplatin resistance of ovarian cancer. Oncol Res. 2023;32(2):373\u201391.","journal-title":"Oncol Res"},{"key":"6508_CR191","doi-asserted-by":"crossref","unstructured":"Mei D, Zhu Y, Zhang L, Wei W. The Role of CTHRC1 in Regulation of Multiple Signaling and Tumor Progression and Metastasis. Mediators Inflamm 2020, 2020:9578701.","DOI":"10.1155\/2020\/9578701"},{"issue":"26","key":"6508_CR192","doi-asserted-by":"publisher","first-page":"4503","DOI":"10.1038\/s41388-021-01865-8","volume":"40","author":"YH Wu","year":"2021","unstructured":"Wu YH, Huang YF, Chang TH, Chen CC, Wu PY, Huang SC, Chou CY. COL11A1 activates cancer-associated fibroblasts by modulating TGF-beta3 through the NF-kappaB\/IGFBP2 axis in ovarian cancer cells. Oncogene. 2021;40(26):4503\u201319.","journal-title":"Oncogene"},{"issue":"1","key":"6508_CR193","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12929-022-00888-x","volume":"29","author":"SC Lin","year":"2022","unstructured":"Lin SC, Liao YC, Chen PM, Yang YY, Wang YH, Tung SL, Chuang CM, Sung YW, Jang TH, Chuang SE, et al. Periostin promotes ovarian cancer metastasis by enhancing M2 macrophages and cancer-associated fibroblasts via integrin-mediated NF-kappaB and TGF-beta2 signaling. J Biomed Sci. 2022;29(1):109.","journal-title":"J Biomed Sci"},{"issue":"16","key":"6508_CR194","doi-asserted-by":"publisher","first-page":"5016","DOI":"10.1158\/0008-5472.CAN-13-0023","volume":"73","author":"TL Yeung","year":"2013","unstructured":"Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC. TGF-beta modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 2013;73(16):5016\u201328.","journal-title":"Cancer Res"},{"issue":"10","key":"6508_CR195","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1172\/JCI62229","volume":"122","author":"SY Ko","year":"2012","unstructured":"Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, Naora H. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest. 2012;122(10):3603\u201317.","journal-title":"J Clin Invest"},{"issue":"1","key":"6508_CR196","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41467-018-03348-z","volume":"9","author":"AM Givel","year":"2018","unstructured":"Givel AM, Kieffer Y, Scholer-Dahirel A, Sirven P, Cardon M, Pelon F, Magagna I, Gentric G, Costa A, Bonneau C, et al. miR200-regulated CXCL12beta promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat Commun. 2018;9(1):1056.","journal-title":"Nat Commun"},{"issue":"40","key":"6508_CR197","doi-asserted-by":"publisher","first-page":"67315","DOI":"10.18632\/oncotarget.18621","volume":"8","author":"R Wei","year":"2017","unstructured":"Wei R, Lv M, Li F, Cheng T, Zhang Z, Jiang G, Zhou Y, Gao R, Wei X, Lou J, et al. Human CAFs promote lymphangiogenesis in ovarian cancer via the Hh-VEGF-C signaling axis. Oncotarget. 2017;8(40):67315\u201328.","journal-title":"Oncotarget"},{"issue":"3","key":"6508_CR198","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ajpath.2010.12.008","volume":"178","author":"ML Henriksson","year":"2011","unstructured":"Henriksson ML, Edin S, Dahlin AM, Oldenborg PA, Oberg A, Van Guelpen B, Rutegard J, Stenling R, Palmqvist R. Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1\/FGFR3 signaling and increased invasion. Am J Pathol. 2011;178(3):1387\u201394.","journal-title":"Am J Pathol"},{"key":"6508_CR199","doi-asserted-by":"crossref","unstructured":"Deying W, Feng G, Shumei L, Hui Z, Ming L, Hongqing W. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met\/PI3K\/Akt and GRP78 signalling in ovarian cancer cells. Biosci Rep 2017, 37(2).","DOI":"10.1042\/BSR20160470"},{"issue":"4","key":"6508_CR200","first-page":"482","volume":"1","author":"P Cirri","year":"2011","unstructured":"Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res. 2011;1(4):482\u201397.","journal-title":"Am J Cancer Res"},{"key":"6508_CR201","doi-asserted-by":"publisher","first-page":"684505","DOI":"10.3389\/fcell.2021.684505","volume":"9","author":"Z Ji","year":"2021","unstructured":"Ji Z, Tian W, Gao W, Zang R, Wang H, Yang G. Cancer-Associated Fibroblast-Derived Interleukin-8 promotes ovarian Cancer cell stemness and malignancy through the Notch3-Mediated signaling. Front Cell Dev Biol. 2021;9:684505.","journal-title":"Front Cell Dev Biol"},{"key":"6508_CR202","doi-asserted-by":"publisher","first-page":"14206","DOI":"10.1038\/ncomms14206","volume":"8","author":"JR Hernandez-Fernaud","year":"2017","unstructured":"Hernandez-Fernaud JR, Ruengeler E, Casazza A, Neilson LJ, Pulleine E, Santi A, Ismail S, Lilla S, Dhayade S, MacPherson IR, et al. Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nat Commun. 2017;8:14206.","journal-title":"Nat Commun"},{"issue":"1","key":"6508_CR203","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41467-018-07987-0","volume":"10","author":"N Ferrari","year":"2019","unstructured":"Ferrari N, Ranftl R, Chicherova I, Slaven ND, Moeendarbary E, Farrugia AJ, Lam M, Semiannikova M, Westergaard MCW, Tchou J, et al. Dickkopf-3 links HSF1 and YAP\/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts. Nat Commun. 2019;10(1):130.","journal-title":"Nat Commun"},{"issue":"6","key":"6508_CR204","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1158\/0008-5472.CAN-16-1615","volume":"77","author":"L Zhao","year":"2017","unstructured":"Zhao L, Ji G, Le X, Wang C, Xu L, Feng M, Zhang Y, Yang H, Xuan Y, Yang Y, et al. Long noncoding RNA LINC00092 acts in Cancer-Associated fibroblasts to drive Glycolysis and progression of ovarian Cancer. Cancer Res. 2017;77(6):1369\u201382.","journal-title":"Cancer Res"},{"issue":"4","key":"6508_CR205","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/med.21473","volume":"38","author":"C Thuwajit","year":"2018","unstructured":"Thuwajit C, Ferraresi A, Titone R, Thuwajit P, Isidoro C. The metabolic cross-talk between epithelial cancer cells and stromal fibroblasts in ovarian cancer progression: autophagy plays a role. Med Res Rev. 2018;38(4):1235\u201354.","journal-title":"Med Res Rev"},{"issue":"2","key":"6508_CR206","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.ygyno.2022.09.003","volume":"167","author":"S Yu","year":"2022","unstructured":"Yu S, Yang R, Xu T, Li X, Wu S, Zhang J. Cancer-associated fibroblasts-derived FMO2 as a biomarker of macrophage infiltration and prognosis in epithelial ovarian cancer. Gynecol Oncol. 2022;167(2):342\u201353.","journal-title":"Gynecol Oncol"},{"key":"6508_CR207","doi-asserted-by":"publisher","first-page":"6403","DOI":"10.1016\/j.csbj.2022.11.025","volume":"20","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Mei S, Huang Y, Chen J, Zhang X, Zhang P. Integrative analysis Deciphers the heterogeneity of cancer-associated fibroblast and implications on clinical outcomes in ovarian cancers. Comput Struct Biotechnol J. 2022;20:6403\u201311.","journal-title":"Comput Struct Biotechnol J"},{"key":"6508_CR208","doi-asserted-by":"publisher","first-page":"1089068","DOI":"10.3389\/fcell.2023.1089068","volume":"11","author":"M Sarkar","year":"2023","unstructured":"Sarkar M, Nguyen T, Gundre E, Ogunlusi O, El-Sobky M, Giri B, Sarkar TR. Cancer-associated fibroblasts: the chief architect in the tumor microenvironment. Front Cell Dev Biol. 2023;11:1089068.","journal-title":"Front Cell Dev Biol"},{"issue":"5","key":"6508_CR209","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.cell.2016.04.009","volume":"165","author":"W Wang","year":"2016","unstructured":"Wang W, Kryczek I, Dostal L, Lin H, Tan L, Zhao L, Lu F, Wei S, Maj T, Peng D, et al. Effector T cells abrogate Stroma-Mediated chemoresistance in ovarian Cancer. Cell. 2016;165(5):1092\u2013105.","journal-title":"Cell"},{"issue":"4","key":"6508_CR210","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.cell.2018.01.009","volume":"172","author":"S Su","year":"2018","unstructured":"Su S, Chen J, Yao H, Liu J, Yu S, Lao L, Wang M, Luo M, Xing Y, Chen F, et al. CD10(+)GPR77(+) Cancer-Associated fibroblasts promote Cancer formation and chemoresistance by sustaining Cancer stemness. Cell. 2018;172(4):841\u2013e856816.","journal-title":"Cell"},{"issue":"1","key":"6508_CR211","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/stem.1556","volume":"32","author":"Y Kinugasa","year":"2014","unstructured":"Kinugasa Y, Matsui T, Takakura N. CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells. 2014;32(1):145\u201356.","journal-title":"Stem Cells"},{"issue":"2","key":"6508_CR212","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1172\/JCI95200","volume":"128","author":"CS Leung","year":"2018","unstructured":"Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, et al. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest. 2018;128(2):589\u2013606.","journal-title":"J Clin Invest"},{"key":"6508_CR213","doi-asserted-by":"publisher","first-page":"11150","DOI":"10.1038\/ncomms11150","volume":"7","author":"CL Au Yeung","year":"2016","unstructured":"Au Yeung CL, Co NN, Tsuruga T, Yeung TL, Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, et al. Exosomal transfer of stroma-derived miR21 confers Paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;7:11150.","journal-title":"Nat Commun"},{"key":"6508_CR214","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12935-019-1051-3","volume":"19","author":"H Guo","year":"2019","unstructured":"Guo H, Ha C, Dong H, Yang Z, Ma Y, Ding Y. Cancer-associated fibroblast-derived Exosomal microRNA-98-5p promotes cisplatin resistance in ovarian cancer by targeting CDKN1A. Cancer Cell Int. 2019;19:347.","journal-title":"Cancer Cell Int"},{"key":"6508_CR215","doi-asserted-by":"publisher","first-page":"798680","DOI":"10.3389\/fonc.2022.798680","volume":"12","author":"M Wessolly","year":"2022","unstructured":"Wessolly M, Mairinger E, Borchert S, Bankfalvi A, Mach P, Schmid KW, Kimmig R, Buderath P, Mairinger FD. CAF-Associated paracrine signaling worsens outcome and potentially contributes to chemoresistance in epithelial ovarian Cancer. Front Oncol. 2022;12:798680.","journal-title":"Front Oncol"},{"issue":"8","key":"6508_CR216","first-page":"4113","volume":"24","author":"HW Jiang","year":"2020","unstructured":"Jiang HW, Li L, Jiang P, Wang YF. MicroRNA-489 targets XIAP to inhibit the biological progression of ovarian cancer via regulating PI3K\/Akt signaling pathway and epithelial-to-mesenchymal transition. Eur Rev Med Pharmacol Sci. 2020;24(8):4113\u201322.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"8","key":"6508_CR217","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","volume":"26","author":"B Izar","year":"2020","unstructured":"Izar B, Tirosh I, Stover EH, Wakiro I, Cuoco MS, Alter I, Rodman C, Leeson R, Su MJ, Shah P, et al. A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020;26(8):1271\u20139.","journal-title":"Nat Med"},{"issue":"32","key":"6508_CR218","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.2217\/fon-2020-0095","volume":"16","author":"F Zhang","year":"2020","unstructured":"Zhang F, Cui JY, Gao HF, Yu H, Gao FF, Chen JL, Chen L. Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12\/CXCR4 axis. Future Oncol. 2020;16(32):2619\u201333.","journal-title":"Future Oncol"},{"issue":"6","key":"6508_CR219","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5483\/BMBRep.2020.53.6.060","volume":"53","author":"D Lim","year":"2020","unstructured":"Lim D, Do Y, Kwon BS, Chang W, Lee MS, Kim J, Cho JG. Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer. BMB Rep. 2020;53(6):291\u20138.","journal-title":"BMB Rep"},{"issue":"5","key":"6508_CR220","first-page":"2287","volume":"25","author":"J Wang","year":"2020","unstructured":"Wang J, Zhu M, Zhou X, Wang T, Zhang J. Changes in tumor markers, coagulation function and serum VEGF in patients with ovarian cancer and benign ovarian disease. J BUON. 2020;25(5):2287\u201392.","journal-title":"J BUON"},{"issue":"6","key":"6508_CR221","first-page":"1105","volume":"74","author":"GM Abu-Jawdeh","year":"1996","unstructured":"Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF, Brown LF. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest. 1996;74(6):1105\u201315.","journal-title":"Lab Invest"},{"issue":"3","key":"6508_CR222","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1007\/s13277-015-4198-0","volume":"37","author":"N Zhan","year":"2016","unstructured":"Zhan N, Dong WG, Wang J. The clinical significance of vascular endothelial growth factor in malignant Ascites. Tumour Biol. 2016;37(3):3719\u201325.","journal-title":"Tumour Biol"},{"issue":"4","key":"6508_CR223","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10434-999-0373-0","volume":"6","author":"BK Zebrowski","year":"1999","unstructured":"Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant Ascites. Ann Surg Oncol. 1999;6(4):373\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"6508_CR224","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.ygyno.2007.10.018","volume":"108","author":"A Bamias","year":"2008","unstructured":"Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, et al. Correlation of NK T-like CD3\u2009+\u2009CD56\u2009+\u2009cells and CD4\u2009+\u2009CD25+(hi) regulatory T cells with VEGF and TNFalpha in Ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecol Oncol. 2008;108(2):421\u20137.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"6508_CR225","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1600-0463.2004.apm1120904.x","volume":"112","author":"I Nascimento","year":"2004","unstructured":"Nascimento I, Schaer R, Lemaire D, Freire S, Paule B, Carvalho S, Meyer R, Schaer-Barbosa H. Vascular endothelial growth factor (VEGF) levels as a tool to discriminate between malignant and nonmalignant Ascites. APMIS. 2004;112(9):585\u20137.","journal-title":"APMIS"},{"issue":"2","key":"6508_CR226","doi-asserted-by":"publisher","first-page":"e55309","DOI":"10.1371\/journal.pone.0055309","volume":"8","author":"D Cheng","year":"2013","unstructured":"Cheng D, Liang B, Li Y. Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer. PLoS ONE. 2013;8(2):e55309.","journal-title":"PLoS ONE"},{"issue":"10","key":"6508_CR227","first-page":"3193","volume":"8","author":"BC Cooper","year":"2002","unstructured":"Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJ, Sood AK. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002;8(10):3193\u20137.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6508_CR228","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3109\/00365513.2013.773593","volume":"73","author":"B Liang","year":"2013","unstructured":"Liang B, Guo Z, Li Y, Liu C. Elevated VEGF concentrations in Ascites and serum predict adverse prognosis in ovarian cancer. Scand J Clin Lab Invest. 2013;73(4):309\u201314.","journal-title":"Scand J Clin Lab Invest"},{"issue":"3","key":"6508_CR229","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ygyno.2014.03.574","volume":"133","author":"P Wimberger","year":"2014","unstructured":"Wimberger P, Chebouti I, Kasimir-Bauer S, Lachmann R, Kuhlisch E, Kimmig R, Suleyman E, Kuhlmann JD. Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance. Gynecol Oncol. 2014;133(3):467\u201372.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"6508_CR230","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2217\/fon-2016-0299","volume":"13","author":"GR Camerin","year":"2017","unstructured":"Camerin GR, Brito AB, Vassallo J, Derchain SF, Lima CS. VEGF gene polymorphisms and outcome of epithelial ovarian cancer patients. Future Oncol. 2017;13(5):409\u201314.","journal-title":"Future Oncol"},{"issue":"2","key":"6508_CR231","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ccr.2010.06.016","volume":"18","author":"C Lu","year":"2010","unstructured":"Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, et al. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010;18(2):185\u201397.","journal-title":"Cancer Cell"},{"issue":"7","key":"6508_CR232","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-07-0118","volume":"6","author":"T Hagemann","year":"2007","unstructured":"Hagemann T, Robinson SC, Thompson RG, Charles K, Kulbe H, Balkwill FR. Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis. Mol Cancer Ther. 2007;6(7):1993\u20132002.","journal-title":"Mol Cancer Ther"},{"key":"6508_CR233","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1038\/ncomms3427","volume":"4","author":"CV Pecot","year":"2013","unstructured":"Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu C, Wu S, Han HD, Shah MY, Rodriguez-Aguayo C, et al. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013;4:2427.","journal-title":"Nat Commun"},{"issue":"5","key":"6508_CR234","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1002\/ctm2.425","volume":"11","author":"J Wang","year":"2021","unstructured":"Wang J, Wang C, Li Y, Li M, Zhu T, Shen Z, Wang H, Lv W, Wang X, Cheng X, et al. Potential of peptide-engineered exosomes with overexpressed miR-92b-3p in anti-angiogenic therapy of ovarian cancer. Clin Transl Med. 2021;11(5):e425.","journal-title":"Clin Transl Med"},{"issue":"26","key":"6508_CR235","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484\u201396.","journal-title":"N Engl J Med"},{"issue":"26","key":"6508_CR236","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473\u201383.","journal-title":"N Engl J Med"},{"key":"6508_CR237","doi-asserted-by":"crossref","unstructured":"Bais C, Mueller B, Brady MF, Mannel RS, Burger RA, Wei W, Marien KM, Kockx MM, Husain A, Birrer MJ et al. Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses. J Natl Cancer Inst 2017, 109(11).","DOI":"10.1093\/jnci\/djx066"},{"key":"6508_CR238","doi-asserted-by":"crossref","unstructured":"Mogi K, Yoshihara M, Iyoshi S, Kitami K, Uno K, Tano S, Koya Y, Sugiyama M, Yamakita Y, Nawa A et al. Ovarian Cancer-Associated mesothelial cells: transdifferentiation to minions of Cancer and orchestrate developing peritoneal dissemination. Cancers (Basel) 2021, 13(6).","DOI":"10.3390\/cancers13061352"},{"issue":"3","key":"6508_CR239","doi-asserted-by":"publisher","first-page":"C721","DOI":"10.1152\/ajpcell.00461.2022","volume":"325","author":"DE Jazwinska","year":"2023","unstructured":"Jazwinska DE, Kulawiec DG, Zervantonakis IK. Cancer-mesothelial and cancer-macrophage interactions in the ovarian cancer microenvironment. Am J Physiol Cell Physiol. 2023;325(3):C721\u201330.","journal-title":"Am J Physiol Cell Physiol"},{"key":"6508_CR240","doi-asserted-by":"crossref","unstructured":"Bajwa P, Kordylewicz K, Bilecz A, Lastra RR, Wroblewski K, Rinkevich Y, Lengyel E, Kenny HA. Cancer-associated mesothelial cell-derived ANGPTL4 and STC1 promote the early steps of ovarian cancer metastasis. JCI Insight 2023, 8(6).","DOI":"10.1172\/jci.insight.163019"},{"key":"6508_CR241","doi-asserted-by":"crossref","unstructured":"Pakula M, Uruski P, Niklas A, Wozniak A, Szpurek D, Tykarski A, Mikula-Pietrasik J, Ksiazek K. A unique pattern of Mesothelial-Mesenchymal transition induced in the normal peritoneal mesothelium by High-Grade serous ovarian Cancer. Cancers (Basel) 2019, 11(5).","DOI":"10.3390\/cancers11050662"},{"key":"6508_CR242","doi-asserted-by":"publisher","first-page":"1013506","DOI":"10.3389\/fimmu.2022.1013506","volume":"13","author":"A Zheng","year":"2022","unstructured":"Zheng A, Wei Y, Zhao Y, Zhang T, Ma X. The role of cancer-associated mesothelial cells in the progression and therapy of ovarian cancer. Front Immunol. 2022;13:1013506.","journal-title":"Front Immunol"},{"issue":"1","key":"6508_CR243","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10585-019-09993-y","volume":"37","author":"H Yasui","year":"2020","unstructured":"Yasui H, Kajiyama H, Tamauchi S, Suzuki S, Peng Y, Yoshikawa N, Sugiyama M, Nakamura K, Kikkawa F. CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway. Clin Exp Metastasis. 2020;37(1):145\u201358.","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"6508_CR244","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1006\/cyto.1995.0073","volume":"7","author":"FA Offner","year":"1995","unstructured":"Offner FA, Obrist P, Stadlmann S, Feichtinger H, Klingler P, Herold M, Zwierzina H, Hittmair A, Mikuz G, Abendstein B, et al. IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine. 1995;7(6):542\u20137.","journal-title":"Cytokine"},{"issue":"6","key":"6508_CR245","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1016\/S0002-9440(10)65516-2","volume":"155","author":"MV Cronauer","year":"1999","unstructured":"Cronauer MV, Stadlmann S, Klocker H, Abendstein B, Eder IE, Rogatsch H, Zeimet AG, Marth C, Offner FA. Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells: induction by interleukin-1. Am J Pathol. 1999;155(6):1977\u201384.","journal-title":"Am J Pathol"},{"issue":"3","key":"6508_CR246","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ygyno.2005.02.017","volume":"97","author":"S Stadlmann","year":"2005","unstructured":"Stadlmann S, Amberger A, Pollheimer J, Gastl G, Offner FA, Margreiter R, Zeimet AG. Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol Oncol. 2005;97(3):784\u20139.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"6508_CR247","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1158\/0008-5472.CAN-05-1292","volume":"66","author":"J Ren","year":"2006","unstructured":"Ren J, Xiao YJ, Singh LS, Zhao X, Zhao Z, Feng L, Rose TM, Prestwich GD, Xu Y. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration, and invasion of ovarian cancer cells. Cancer Res. 2006;66(6):3006\u201314.","journal-title":"Cancer Res"},{"issue":"22","key":"6508_CR248","first-page":"6410","volume":"62","author":"EL Hiltunen","year":"2002","unstructured":"Hiltunen EL, Anttila M, Kultti A, Ropponen K, Penttinen J, Yliskoski M, Kuronen AT, Juhola M, Tammi R, Tammi M, et al. Elevated hyaluronan concentration without hyaluronidase activation in malignant epithelial ovarian tumors. Cancer Res. 2002;62(22):6410\u20133.","journal-title":"Cancer Res"},{"issue":"7","key":"6508_CR249","first-page":"1228","volume":"57","author":"T Strobel","year":"1997","unstructured":"Strobel T, Swanson L, Cannistra SA. In vivo Inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation. Cancer Res. 1997;57(7):1228\u201332.","journal-title":"Cancer Res"},{"issue":"2","key":"6508_CR250","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1046\/j.1365-2141.2003.04282.x","volume":"121","author":"T Vincent","year":"2003","unstructured":"Vincent T, Molina L, Espert L, Mechti N. Hyaluronan, a major non-protein glycosaminoglycan component of the extracellular matrix in human bone marrow, mediates dexamethasone resistance in multiple myeloma. Br J Haematol. 2003;121(2):259\u201369.","journal-title":"Br J Haematol"},{"key":"6508_CR251","doi-asserted-by":"crossref","unstructured":"Coleman KL, Chiaramonti M, Haddad B, Ranzenberger R, Henning H, Al Khashali H, Ray R, Darweesh B, Guthrie J, Heyl D et al. Phosphorylation of IGFBP-3 by casein kinase 2 blocks its interaction with hyaluronan, enabling HA-CD44 signaling leading to increased NSCLC cell survival and cisplatin resistance. Cells 2023, 12(3).","DOI":"10.3390\/cells12030405"},{"issue":"25","key":"6508_CR252","doi-asserted-by":"publisher","first-page":"17635","DOI":"10.1074\/jbc.M800109200","volume":"283","author":"LY Bourguignon","year":"2008","unstructured":"Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem. 2008;283(25):17635\u201351.","journal-title":"J Biol Chem"},{"key":"6508_CR253","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1186\/1471-2407-13-476","volume":"13","author":"C Ricciardelli","year":"2013","unstructured":"Ricciardelli C, Ween MP, Lokman NA, Tan IA, Pyragius CE, Oehler MK. Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer. BMC Cancer. 2013;13:476.","journal-title":"BMC Cancer"},{"key":"6508_CR254","doi-asserted-by":"crossref","unstructured":"Qian J, LeSavage BL, Hubka KM, Ma C, Natarajan S, Eggold JT, Xiao Y, Fuh KC, Krishnan V, Enejder A et al. Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling. J Clin Invest 2021, 131(16).","DOI":"10.1172\/JCI146186"},{"key":"6508_CR255","doi-asserted-by":"crossref","unstructured":"Balduit A, Agostinis C, Mangogna A, Maggi V, Zito G, Romano F, Romano A, Ceccherini R, Grassi G, Bonin S et al. The Extracellular Matrix Influences Ovarian Carcinoma Cells\u2019 Sensitivity to Cisplatinum: A First Step towards Personalized Medicine. Cancers (Basel) 2020, 12(5).","DOI":"10.3390\/cancers12051175"},{"issue":"4","key":"6508_CR256","first-page":"2105","volume":"40","author":"A Shishido","year":"2018","unstructured":"Shishido A, Mori S, Yokoyama Y, Hamada Y, Minami K, Qian Y, Wang J, Hirose H, Wu X, Kawaguchi N, et al. Mesothelial cells facilitate cancer stem\u2013like properties in spheroids of ovarian cancer cells. Oncol Rep. 2018;40(4):2105\u201314.","journal-title":"Oncol Rep"},{"issue":"2","key":"6508_CR257","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<303::AID-IJC21>3.0.CO;2-W","volume":"80","author":"M Rieppi","year":"1999","unstructured":"Rieppi M, Vergani V, Gatto C, Zanetta G, Allavena P, Taraboletti G, Giavazzi R. Mesothelial cells induce the motility of human ovarian carcinoma cells. Int J Cancer. 1999;80(2):303\u20137.","journal-title":"Int J Cancer"},{"issue":"8","key":"6508_CR258","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1002\/ijc.32854","volume":"146","author":"M Yoshihara","year":"2020","unstructured":"Yoshihara M, Kajiyama H, Yokoi A, Sugiyama M, Koya Y, Yamakita Y, Liu W, Nakamura K, Moriyama Y, Yasui H, et al. Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1\/Akt signaling pathway. Int J Cancer. 2020;146(8):2268\u201380.","journal-title":"Int J Cancer"},{"issue":"1","key":"6508_CR259","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13073-021-00922-x","volume":"13","author":"S Olbrecht","year":"2021","unstructured":"Olbrecht S, Busschaert P, Qian J, Vanderstichele A, Loverix L, Van Gorp T, Van Nieuwenhuysen E, Han S, Van den Broeck A, Coosemans A, et al. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification. Genome Med. 2021;13(1):111.","journal-title":"Genome Med"},{"issue":"6","key":"6508_CR260","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/cncr.30415","volume":"123","author":"JM Scalici","year":"2017","unstructured":"Scalici JM, Arapovic S, Saks EJ, Atkins KA, Petroni G, Duska LR, Slack-Davis JK. Mesothelium expression of vascular cell adhesion molecule-1 (VCAM-1) is associated with an unfavorable prognosis in epithelial ovarian cancer (EOC). Cancer. 2017;123(6):977\u201384.","journal-title":"Cancer"},{"issue":"1","key":"6508_CR261","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13045-021-01208-w","volume":"14","author":"T Lan","year":"2021","unstructured":"Lan T, Luo M, Wei X. Mesenchymal stem\/stromal cells in cancer therapy. J Hematol Oncol. 2021;14(1):195.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"6508_CR262","doi-asserted-by":"publisher","first-page":"30015","DOI":"10.3390\/ijms161226215","volume":"16","author":"KJ Rhee","year":"2015","unstructured":"Rhee KJ, Lee JI, Eom YW. Mesenchymal stem Cell-Mediated effects of tumor support or suppression. Int J Mol Sci. 2015;16(12):30015\u201333.","journal-title":"Int J Mol Sci"},{"key":"6508_CR263","doi-asserted-by":"crossref","unstructured":"Lin W, Huang L, Li Y, Fang B, Li G, Chen L, Xu L. Mesenchymal Stem Cells and Cancer: Clinical Challenges and Opportunities. Biomed Res Int 2019, 2019:2820853.","DOI":"10.1155\/2019\/2820853"},{"issue":"8","key":"6508_CR264","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1172\/JCI45273","volume":"121","author":"K McLean","year":"2011","unstructured":"McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, Cabrera L, Keller E, McCauley L, Cho KR, et al. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J Clin Invest. 2011;121(8):3206\u201319.","journal-title":"J Clin Invest"},{"issue":"2","key":"6508_CR265","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/scrt189","volume":"4","author":"CM Gomes","year":"2013","unstructured":"Gomes CM. The dual role of mesenchymal stem cells in tumor progression. Stem Cell Res Ther. 2013;4(2):42.","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"6508_CR266","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/stem.2932","volume":"37","author":"LG Coffman","year":"2019","unstructured":"Coffman LG, Pearson AT, Frisbie LG, Freeman Z, Christie E, Bowtell DD, Buckanovich RJ. Ovarian Carcinoma-Associated mesenchymal stem cells arise from Tissue-Specific normal stroma. Stem Cells. 2019;37(2):257\u201369.","journal-title":"Stem Cells"},{"issue":"9","key":"6508_CR267","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1038\/s41375-020-0775-3","volume":"34","author":"C Xia","year":"2020","unstructured":"Xia C, Wang T, Cheng H, Dong Y, Weng Q, Sun G, Zhou P, Wang K, Liu X, Geng Y, et al. Mesenchymal stem cells suppress leukemia via macrophage-mediated functional restoration of bone marrow microenvironment. Leukemia. 2020;34(9):2375\u201383.","journal-title":"Leukemia"},{"issue":"3","key":"6508_CR268","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00441-016-2364-3","volume":"363","author":"H Niknejad","year":"2016","unstructured":"Niknejad H, Yazdanpanah G, Ahmadiani A. Induction of apoptosis, stimulation of cell-cycle arrest and Inhibition of angiogenesis make human amnion-derived cells promising sources for cell therapy of cancer. Cell Tissue Res. 2016;363(3):599\u2013608.","journal-title":"Cell Tissue Res"},{"key":"6508_CR269","doi-asserted-by":"crossref","unstructured":"Liu QY, Ruan F, Li JY, Wei L, Hu P, Chen HW, Liu QW. Human Menstrual Blood-Derived Stem Cells Inhibit the Proliferation of HeLa Cells via TGF-beta1-Mediated JNK\/P21 Signaling Pathways. Stem Cells Int 2019, 2019:9280298.","DOI":"10.1155\/2019\/9280298"},{"issue":"2","key":"6508_CR270","first-page":"189","volume":"51","author":"IB Johnstone","year":"1987","unstructured":"Johnstone IB, Crane S. The effects of Desmopressin on plasma factor VIII\/von Willebrand factor activity in dogs with von Willebrand\u2019s disease. Can J Vet Res. 1987;51(2):189\u201393.","journal-title":"Can J Vet Res"},{"issue":"2","key":"6508_CR271","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cncr.24032","volume":"115","author":"JA Cho","year":"2009","unstructured":"Cho JA, Park H, Kim HK, Lim EH, Seo SW, Choi JS, Lee KW. Hyperthermia-treated mesenchymal stem cells exert antitumor effects on human carcinoma cell line. Cancer. 2009;115(2):311\u201323.","journal-title":"Cancer"},{"issue":"5","key":"6508_CR272","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1089\/scd.2012.0304","volume":"22","author":"S Bruno","year":"2013","unstructured":"Bruno S, Collino F, Deregibus MC, Grange C, Tetta C, Camussi G. Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev. 2013;22(5):758\u201371.","journal-title":"Stem Cells Dev"},{"issue":"5","key":"6508_CR273","first-page":"4521","volume":"17","author":"G Kalamegam","year":"2019","unstructured":"Kalamegam G, Sait KHW, Anfinan N, Kadam R, Ahmed F, Rasool M, Naseer MI, Pushparaj PN, Al-Qahtani M. Cytokines secreted by human Wharton\u2019s jelly stem cells inhibit the proliferation of ovarian cancer (OVCAR3) cells in vitro. Oncol Lett. 2019;17(5):4521\u201331.","journal-title":"Oncol Lett"},{"issue":"6","key":"6508_CR274","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/jcb.24073","volume":"113","author":"K Gauthaman","year":"2012","unstructured":"Gauthaman K, Yee FC, Cheyyatraivendran S, Biswas A, Choolani M, Bongso A. Human umbilical cord Wharton\u2019s jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro. J Cell Biochem. 2012;113(6):2027\u201339.","journal-title":"J Cell Biochem"},{"issue":"43","key":"6508_CR275","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.18632\/oncotarget.27065","volume":"10","author":"Y Zeng","year":"2019","unstructured":"Zeng Y, Li B, Li T, Liu W, Ran C, Penson RT, Poznansky MC, Du Y, Chen H. CD90(low) MSCs modulate intratumoral immunity to confer antitumor activity in a mouse model of ovarian cancer. Oncotarget. 2019;10(43):4479\u201391.","journal-title":"Oncotarget"},{"issue":"5","key":"6508_CR276","doi-asserted-by":"publisher","first-page":"570","DOI":"10.21873\/cgp.20341","volume":"19","author":"J Sendon-Lago","year":"2022","unstructured":"Sendon-Lago J, Seoane S, Saleh F, Garcia-Caballero L, Arias ME, Eiro N, Macia M, Vizoso FJ, Perez-Fernandez R, Schneider J. In vivo effects of conditioned medium from human uterine cervical stem cells in an ovarian Cancer xenograft mouse model. Cancer Genomics Proteom. 2022;19(5):570\u20135.","journal-title":"Cancer Genomics Proteom"},{"issue":"1","key":"6508_CR277","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/0973-1482.131451","volume":"10","author":"S Rezaeifard","year":"2014","unstructured":"Rezaeifard S, Razmkhah M, Robati M, Momtahan M, Ghaderi A. Adipose derived stem cells isolated from omentum: a novel source of chemokines for ovarian cancer growth. J Cancer Res Ther. 2014;10(1):159\u201364.","journal-title":"J Cancer Res Ther"},{"issue":"12","key":"6508_CR278","doi-asserted-by":"publisher","first-page":"e81859","DOI":"10.1371\/journal.pone.0081859","volume":"8","author":"A Nowicka","year":"2013","unstructured":"Nowicka A, Marini FC, Solley TN, Elizondo PB, Zhang Y, Sharp HJ, Broaddus R, Kolonin M, Mok SC, Thompson MS, et al. Human omental-derived adipose stem cells increase ovarian cancer proliferation, migration, and chemoresistance. PLoS ONE. 2013;8(12):e81859.","journal-title":"PLoS ONE"},{"key":"6508_CR279","doi-asserted-by":"publisher","first-page":"756011","DOI":"10.3389\/fonc.2021.756011","volume":"11","author":"X Liu","year":"2021","unstructured":"Liu X, Zhao G, Huo X, Wang Y, Tigyi G, Zhu BM, Yue J, Zhang W. Adipose-Derived stem cells facilitate ovarian tumor growth and metastasis by promoting epithelial to mesenchymal transition through activating the TGF-beta pathway. Front Oncol. 2021;11:756011.","journal-title":"Front Oncol"},{"issue":"1","key":"6508_CR280","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1186\/s12885-018-4918-0","volume":"18","author":"T Gao","year":"2018","unstructured":"Gao T, Yu Y, Cong Q, Wang Y, Sun M, Yao L, Xu C, Jiang W. Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor. BMC Cancer. 2018;18(1):999.","journal-title":"BMC Cancer"},{"issue":"1","key":"6508_CR281","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.yexcr.2015.07.020","volume":"337","author":"Y Chu","year":"2015","unstructured":"Chu Y, Tang H, Guo Y, Guo J, Huang B, Fang F, Cai J, Wang Z. Adipose-derived mesenchymal stem cells promote cell proliferation and invasion of epithelial ovarian cancer. Exp Cell Res. 2015;337(1):16\u201327.","journal-title":"Exp Cell Res"},{"key":"6508_CR282","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1479-5876-12-59","volume":"12","author":"R Lis","year":"2014","unstructured":"Lis R, Touboul C, Halabi NM, Madduri AS, Querleu D, Mezey J, Malek JA, Suhre K, Rafii A. Mesenchymal cell interaction with ovarian cancer cells induces a background dependent pro-metastatic transcriptomic profile. J Transl Med. 2014;12:59.","journal-title":"J Transl Med"},{"issue":"9","key":"6508_CR283","doi-asserted-by":"publisher","first-page":"4434","DOI":"10.1111\/jcmm.16511","volume":"25","author":"Y Chu","year":"2021","unstructured":"Chu Y, Zhu C, Wang Q, Liu M, Wan W, Zhou J, Han R, Yang J, Luo W, Liu C, et al. Adipose-derived mesenchymal stem cells induced PAX8 promotes ovarian cancer cell growth by stabilizing TAZ protein. J Cell Mol Med. 2021;25(9):4434\u201343.","journal-title":"J Cell Mol Med"},{"key":"6508_CR284","doi-asserted-by":"crossref","unstructured":"Chu Y, You M, Zhang J, Gao G, Han R, Luo W, Liu T, Zuo J, Wang F. Adipose-Derived Mesenchymal Stem Cells Enhance Ovarian Cancer Growth and Metastasis by Increasing Thymosin Beta 4X-Linked Expression. Stem Cells Int 2019, 2019:9037197.","DOI":"10.1155\/2019\/9037197"},{"issue":"1","key":"6508_CR285","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1478-811X-10-26","volume":"10","author":"R Hass","year":"2012","unstructured":"Hass R, Otte A. Mesenchymal stem cells as all-round supporters in a normal and neoplastic microenvironment. Cell Commun Signal. 2012;10(1):26.","journal-title":"Cell Commun Signal"},{"issue":"6","key":"6508_CR286","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.18632\/oncotarget.6870","volume":"7","author":"LG Coffman","year":"2016","unstructured":"Coffman LG, Choi YJ, McLean K, Allen BL, di Magliano MP, Buckanovich RJ. Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4\/HH signaling loop. Oncotarget. 2016;7(6):6916\u201332.","journal-title":"Oncotarget"},{"issue":"2","key":"6508_CR287","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1158\/0008-5472.CAN-14-1337","volume":"75","author":"B Salimian Rizi","year":"2015","unstructured":"Salimian Rizi B, Caneba C, Nowicka A, Nabiyar AW, Liu X, Chen K, Klopp A, Nagrath D. Nitric oxide mediates metabolic coupling of omentum-derived adipose stroma to ovarian and endometrial cancer cells. Cancer Res. 2015;75(2):456\u201371.","journal-title":"Cancer Res"},{"issue":"2","key":"6508_CR288","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/15548627.2014.998931","volume":"11","author":"SF Zhang","year":"2015","unstructured":"Zhang SF, Wang XY, Fu ZQ, Peng QH, Zhang JY, Ye F, Fu YF, Zhou CY, Lu WG, Cheng XD, et al. TXNDC17 promotes Paclitaxel resistance via inducing autophagy in ovarian cancer. Autophagy. 2015;11(2):225\u201338.","journal-title":"Autophagy"},{"issue":"24","key":"6508_CR289","doi-asserted-by":"publisher","first-page":"17163","DOI":"10.1074\/jbc.M114.558288","volume":"289","author":"J Wang","year":"2014","unstructured":"Wang J, Wu GS. Role of autophagy in cisplatin resistance in ovarian cancer cells. J Biol Chem. 2014;289(24):17163\u201373.","journal-title":"J Biol Chem"},{"issue":"6","key":"6508_CR290","doi-asserted-by":"publisher","first-page":"9587","DOI":"10.3892\/mmr.2017.7783","volume":"16","author":"Y Wen","year":"2017","unstructured":"Wen Y, Guo Y, Huang Z, Cai J, Wang Z. Adipose\u2013derived mesenchymal stem cells attenuate cisplatin\u2013induced apoptosis in epithelial ovarian cancer cells. Mol Med Rep. 2017;16(6):9587\u201392.","journal-title":"Mol Med Rep"},{"issue":"2","key":"6508_CR291","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1002\/ijgo.12800","volume":"145","author":"J Sookram","year":"2019","unstructured":"Sookram J, Zheng A, Linden KM, Morgan AB, Brown SA, Ostrovsky O. Epigenetic therapy can inhibit growth of ovarian cancer cells and reverse chemoresistant properties acquired from metastatic omentum. Int J Gynaecol Obstet. 2019;145(2):225\u201332.","journal-title":"Int J Gynaecol Obstet"},{"key":"6508_CR292","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jconrel.2018.12.019","volume":"294","author":"HH Wu","year":"2019","unstructured":"Wu HH, Zhou Y, Tabata Y, Gao JQ. Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic. J Control Release. 2019;294:102\u201313.","journal-title":"J Control Release"},{"issue":"3","key":"6508_CR293","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.stem.2009.02.001","volume":"4","author":"JM Karp","year":"2009","unstructured":"Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4(3):206\u201316.","journal-title":"Cell Stem Cell"},{"key":"6508_CR294","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.biomaterials.2016.02.024","volume":"88","author":"B Layek","year":"2016","unstructured":"Layek B, Sadhukha T, Prabha S. Glycoengineered mesenchymal stem cells as an enabling platform for two-step targeting of solid tumors. Biomaterials. 2016;88:97\u2013109.","journal-title":"Biomaterials"},{"issue":"10","key":"6508_CR295","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1158\/0008-5472.CAN-08-4698","volume":"69","author":"MR Loebinger","year":"2009","unstructured":"Loebinger MR, Eddaoudi A, Davies D, Janes SM. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009;69(10):4134\u201342.","journal-title":"Cancer Res"},{"issue":"6","key":"6508_CR296","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1158\/1535-7163.MCT-17-0682","volume":"17","author":"B Layek","year":"2018","unstructured":"Layek B, Sadhukha T, Panyam J, Prabha S. Nano-Engineered mesenchymal stem cells increase therapeutic efficacy of anticancer drug through true active tumor targeting. Mol Cancer Ther. 2018;17(6):1196\u2013206.","journal-title":"Mol Cancer Ther"},{"key":"6508_CR297","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.biomaterials.2018.08.024","volume":"182","author":"J Han","year":"2018","unstructured":"Han J, Hwang HS, Na K. TRAIL-secreting human mesenchymal stem cells engineered by a non-viral vector and photochemical internalization for pancreatic cancer gene therapy. Biomaterials. 2018;182:259\u201368.","journal-title":"Biomaterials"},{"issue":"6","key":"6508_CR298","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-20-1499","volume":"27","author":"MI Chastkofsky","year":"2021","unstructured":"Chastkofsky MI, Pituch KC, Katagi H, Zannikou M, Ilut L, Xiao T, Han Y, Sonabend AM, Curiel DT, Bonner ER, et al. Mesenchymal stem cells successfully deliver oncolytic virotherapy to diffuse intrinsic Pontine glioma. Clin Cancer Res. 2021;27(6):1766\u201377.","journal-title":"Clin Cancer Res"},{"issue":"1\u20132\u20133","key":"6508_CR299","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1387\/ijdb.210120nk","volume":"66","author":"A Karampoga","year":"2022","unstructured":"Karampoga A, Tzaferi K, Koutsakis C, Kyriakopoulou K, Karamanos NK. Exosomes and the extracellular matrix: a dynamic interplay in cancer progression. Int J Dev Biol. 2022;66(1\u20132\u20133):97\u2013102.","journal-title":"Int J Dev Biol"},{"issue":"1","key":"6508_CR300","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-019-0991-5","volume":"18","author":"L Mashouri","year":"2019","unstructured":"Mashouri L, Yousefi H, Aref AR, Ahadi AM, Molaei F, Alahari SK. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance. Mol Cancer. 2019;18(1):75.","journal-title":"Mol Cancer"},{"issue":"2","key":"6508_CR301","doi-asserted-by":"publisher","first-page":"113","DOI":"10.4196\/kjpp.2018.22.2.113","volume":"22","author":"YS Kim","year":"2018","unstructured":"Kim YS, Ahn JS, Kim S, Kim HJ, Kim SH, Kang JS. The potential theragnostic (diagnostic\u2009+\u2009therapeutic) application of exosomes in diverse biomedical fields. Korean J Physiol Pharmacol. 2018;22(2):113\u201325.","journal-title":"Korean J Physiol Pharmacol"},{"issue":"7","key":"6508_CR302","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1158\/1541-7786.MCR-17-0784","volume":"16","author":"C Ringuette Goulet","year":"2018","unstructured":"Ringuette Goulet C, Bernard G, Tremblay S, Chabaud S, Bolduc S, Pouliot F. Exosomes induce fibroblast differentiation into Cancer-Associated fibroblasts through TGFbeta signaling. Mol Cancer Res. 2018;16(7):1196\u2013204.","journal-title":"Mol Cancer Res"},{"issue":"6","key":"6508_CR303","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1074\/mcp.M900381-MCP200","volume":"9","author":"JE Park","year":"2010","unstructured":"Park JE, Tan HS, Datta A, Lai RC, Zhang H, Meng W, Lim SK, Sze SK. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteom. 2010;9(6):1085\u201399.","journal-title":"Mol Cell Proteom"},{"issue":"3","key":"6508_CR304","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ygyno.2007.08.064","volume":"107","author":"S Runz","year":"2007","unstructured":"Runz S, Keller S, Rupp C, Stoeck A, Issa Y, Koensgen D, Mustea A, Sehouli J, Kristiansen G, Altevogt P. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol. 2007;107(3):563\u201371.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"6508_CR305","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.4049\/jimmunol.1801041","volume":"201","author":"GN Shenoy","year":"2018","unstructured":"Shenoy GN, Loyall J, Berenson CS, Kelleher RJ Jr., Iyer V, Balu-Iyer SV, Odunsi K, Bankert RB. Sialic Acid-Dependent Inhibition of T cells by Exosomal ganglioside GD3 in ovarian tumor microenvironments. J Immunol. 2018;201(12):3750\u20138.","journal-title":"J Immunol"},{"issue":"3","key":"6508_CR306","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.4049\/jimmunol.176.3.1375","volume":"176","author":"C Liu","year":"2006","unstructured":"Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y, Kappes JC, Barnes S, Kimberly RP, Grizzle WE, et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol. 2006;176(3):1375\u201385.","journal-title":"J Immunol"},{"issue":"11","key":"6508_CR307","doi-asserted-by":"publisher","first-page":"6867","DOI":"10.4049\/jimmunol.178.11.6867","volume":"178","author":"S Yu","year":"2007","unstructured":"Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, Li C, Cong Y, Kimberly R, Grizzle WE, et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol. 2007;178(11):6867\u201375.","journal-title":"J Immunol"},{"issue":"7","key":"6508_CR308","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1158\/0008-5472.CAN-07-0520","volume":"67","author":"R Valenti","year":"2007","unstructured":"Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007;67(7):2912\u20135.","journal-title":"Cancer Res"},{"key":"6508_CR309","doi-asserted-by":"crossref","unstructured":"Kazemi NY, Gendrot B, Berishvili E, Markovic SN, Cohen M. The role and clinical interest of extracellular vesicles in pregnancy and ovarian Cancer. Biomedicines 2021, 9(9).","DOI":"10.3390\/biomedicines9091257"},{"issue":"2","key":"6508_CR310","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/j.1582-4934.2011.01316.x","volume":"16","author":"J Yin","year":"2012","unstructured":"Yin J, Yan X, Yao X, Zhang Y, Shan Y, Mao N, Yang Y, Pan L. Secretion of Annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients. J Cell Mol Med. 2012;16(2):337\u201348.","journal-title":"J Cell Mol Med"},{"key":"6508_CR311","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2017.09.013","volume":"266","author":"SM Kim","year":"2017","unstructured":"Kim SM, Yang Y, Oh SJ, Hong Y, Seo M, Jang M. Cancer-derived exosomes as a delivery platform of CRISPR\/Cas9 confer cancer cell tropism-dependent targeting. J Control Release. 2017;266:8\u201316.","journal-title":"J Control Release"},{"issue":"7","key":"6508_CR312","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/s41388-019-1087-9","volume":"39","author":"M Asare-Werehene","year":"2020","unstructured":"Asare-Werehene M, Nakka K, Reunov A, Chiu CT, Lee WT, Abedini MR, Wang PW, Shieh DB, Dilworth FJ, Carmona E, et al. The exosome-mediated autocrine and paracrine actions of plasma Gelsolin in ovarian cancer chemoresistance. Oncogene. 2020;39(7):1600\u201316.","journal-title":"Oncogene"},{"issue":"18","key":"6508_CR313","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.1158\/0008-5472.CAN-20-0788","volume":"80","author":"M Asare-Werehene","year":"2020","unstructured":"Asare-Werehene M, Communal L, Carmona E, Han Y, Song YS, Burger D, Mes-Masson AM, Tsang BK. Plasma Gelsolin inhibits CD8(+) T-cell function and regulates glutathione production to confer chemoresistance in ovarian Cancer. Cancer Res. 2020;80(18):3959\u201371.","journal-title":"Cancer Res"},{"issue":"9","key":"6508_CR314","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1111\/j.1582-4934.2010.01058.x","volume":"14","author":"SD Li","year":"2010","unstructured":"Li SD, Zhang JR, Wang YQ, Wan XP. The role of MicroRNAs in ovarian cancer initiation and progression. J Cell Mol Med. 2010;14(9):2240\u20139.","journal-title":"J Cell Mol Med"},{"key":"6508_CR315","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jprot.2012.12.029","volume":"80","author":"B Liang","year":"2013","unstructured":"Liang B, Peng P, Chen S, Li L, Zhang M, Cao D, Yang J, Li H, Gui T, Li X, et al. Characterization and proteomic analysis of ovarian cancer-derived exosomes. J Proteom. 2013;80:171\u201382.","journal-title":"J Proteom"},{"issue":"3","key":"6508_CR316","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ygyno.2008.08.017","volume":"111","author":"A Sorrentino","year":"2008","unstructured":"Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G, Ferlini C. Role of MicroRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008;111(3):478\u201386.","journal-title":"Gynecol Oncol"},{"key":"6508_CR317","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ebiom.2018.11.004","volume":"38","author":"P Kanlikilicer","year":"2018","unstructured":"Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, et al. Exosomal MiRNA confers chemo resistance via targeting Cav1\/p-gp\/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2018;38:100\u201312.","journal-title":"EBioMedicine"},{"issue":"1","key":"6508_CR318","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ygyno.2014.12.042","volume":"137","author":"RC Pink","year":"2015","unstructured":"Pink RC, Samuel P, Massa D, Caley DP, Brooks SA, Carter DR. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells. Gynecol Oncol. 2015;137(1):143\u201351.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"6508_CR319","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/cam4.409","volume":"4","author":"K Weiner-Gorzel","year":"2015","unstructured":"Weiner-Gorzel K, Dempsey E, Milewska M, McGoldrick A, Toh V, Walsh A, Lindsay S, Gubbins L, Cannon A, Sharpe D, et al. Overexpression of the MicroRNA miR-433 promotes resistance to Paclitaxel through the induction of cellular senescence in ovarian cancer cells. Cancer Med. 2015;4(5):745\u201358.","journal-title":"Cancer Med"},{"issue":"5","key":"6508_CR320","first-page":"2124","volume":"11","author":"T Li","year":"2021","unstructured":"Li T, Lin L, Liu Q, Gao W, Chen L, Sha C, Chen Q, Xu W, Li Y, Zhu X. Exosomal transfer of miR-429 confers chemoresistance in epithelial ovarian cancer. Am J Cancer Res. 2021;11(5):2124\u201341.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"6508_CR321","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13046-019-1095-1","volume":"38","author":"X Zhu","year":"2019","unstructured":"Zhu X, Shen H, Yin X, Yang M, Wei H, Chen Q, Feng F, Liu Y, Xu W, Li Y. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype. J Exp Clin Cancer Res. 2019;38(1):81.","journal-title":"J Exp Clin Cancer Res"},{"key":"6508_CR322","doi-asserted-by":"publisher","first-page":"1087689","DOI":"10.3389\/fimmu.2022.1087689","volume":"13","author":"H Luo","year":"2022","unstructured":"Luo H, Zhou Y, Zhang J, Zhang Y, Long S, Lin X, Yang A, Duan J, Yang N, Yang Z, et al. NK cell-derived exosomes enhance the anti-tumor effects against ovarian cancer by delivering cisplatin and reactivating NK cell functions. Front Immunol. 2022;13:1087689.","journal-title":"Front Immunol"},{"issue":"3","key":"6508_CR323","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s12015-020-10070-1","volume":"17","author":"K Girigoswami","year":"2021","unstructured":"Girigoswami K, Saini D, Girigoswami A. Extracellular matrix remodeling and development of Cancer. Stem Cell Rev Rep. 2021;17(3):739\u201347.","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"6508_CR324","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","volume":"22","author":"Z Yuan","year":"2023","unstructured":"Yuan Z, Li Y, Zhang S, Wang X, Dou H, Yu X, Zhang Z, Yang S, Xiao M. Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments. Mol Cancer. 2023;22(1):48.","journal-title":"Mol Cancer"},{"issue":"3","key":"6508_CR325","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/2159-8290.CD-17-0284","volume":"8","author":"OMT Pearce","year":"2018","unstructured":"Pearce OMT, Delaine-Smith RM, Maniati E, Nichols S, Wang J, Bohm S, Rajeeve V, Ullah D, Chakravarty P, Jones RR, et al. Deconstruction of a metastatic tumor microenvironment reveals a common matrix response in human cancers. Cancer Discov. 2018;8(3):304\u201319.","journal-title":"Cancer Discov"},{"issue":"9","key":"6508_CR326","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1158\/0008-5472.CAN-18-2616","volume":"79","author":"S Natarajan","year":"2019","unstructured":"Natarajan S, Foreman KM, Soriano MI, Rossen NS, Shehade H, Fregoso DR, Eggold JT, Krishnan V, Dorigo O, Krieg AJ, et al. Collagen remodeling in the hypoxic Tumor-Mesothelial niche promotes ovarian Cancer metastasis. Cancer Res. 2019;79(9):2271\u201384.","journal-title":"Cancer Res"},{"issue":"8","key":"6508_CR327","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.prp.2018.06.007","volume":"214","author":"R Ma","year":"2018","unstructured":"Ma R, Tang Z, Sun K, Ye X, Cheng H, Chang X, Cui H. Low levels of ADAM23 expression in epithelial ovarian cancer are associated with poor survival. Pathol Res Pract. 2018;214(8):1115\u201322.","journal-title":"Pathol Res Pract"},{"issue":"6","key":"6508_CR328","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/carcin\/bgu007","volume":"35","author":"CH Chen","year":"2014","unstructured":"Chen CH, Wang SH, Liu CH, Wu YL, Wang WJ, Huang J, Hung JS, Lai IR, Liang JT, Huang MC. beta-1,4-Galactosyltransferase III suppresses beta1 integrin-mediated invasive phenotypes and negatively correlates with metastasis in colorectal cancer. Carcinogenesis. 2014;35(6):1258\u201366.","journal-title":"Carcinogenesis"},{"issue":"9","key":"6508_CR329","first-page":"1482","volume":"20","author":"Q Li","year":"2010","unstructured":"Li Q, Liu S, Lin B, Yan L, Wang Y, Wang C, Zhang S. Expression and correlation of Lewis y antigen and integrins alpha5 and beta1 in ovarian serous and mucinous carcinoma. Int J Gynecol Cancer. 2010;20(9):1482\u20139.","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"6508_CR330","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1158\/0008-5472.CAN-09-3415","volume":"70","author":"Y Dong","year":"2010","unstructured":"Dong Y, Tan OL, Loessner D, Stephens C, Walpole C, Boyle GM, Parsons PG, Clements JA. Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and Paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res. 2010;70(7):2624\u201333.","journal-title":"Cancer Res"},{"issue":"2","key":"6508_CR331","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ygyno.2009.04.031","volume":"114","author":"L Wang","year":"2009","unstructured":"Wang L, Madigan MC, Chen H, Liu F, Patterson KI, Beretov J, O\u2019Brien PM, Li Y. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol Oncol. 2009;114(2):265\u201372.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"6508_CR332","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/annonc\/mdq462","volume":"22","author":"J Dorn","year":"2011","unstructured":"Dorn J, Harbeck N, Kates R, Gkazepis A, Scorilas A, Soosaipillai A, Diamandis E, Kiechle M, Schmalfeldt B, Schmitt M. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Ann Oncol. 2011;22(4):877\u201383.","journal-title":"Ann Oncol"},{"issue":"7","key":"6508_CR333","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1093\/annonc\/mdn035","volume":"19","author":"A Psyrri","year":"2008","unstructured":"Psyrri A, Kountourakis P, Scorilas A, Markakis S, Camp R, Diamandis EP, Dimopoulos MA, Kowalski D. Human tissue Kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. Ann Oncol. 2008;19(7):1271\u20137.","journal-title":"Ann Oncol"},{"issue":"27","key":"6508_CR334","doi-asserted-by":"publisher","first-page":"23748","DOI":"10.18632\/oncotarget.4250","volume":"6","author":"YH Wu","year":"2015","unstructured":"Wu YH, Chang TH, Huang YF, Chen CC, Chou CY. COL11A1 confers chemoresistance on ovarian cancer cells through the activation of Akt\/c\/EBPbeta pathway and PDK1 stabilization. Oncotarget. 2015;6(27):23748\u201363.","journal-title":"Oncotarget"},{"issue":"4","key":"6508_CR335","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s41419-019-1555-8","volume":"10","author":"YH Wu","year":"2019","unstructured":"Wu YH, Huang YF, Chen CC, Chou CY. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through Inhibition of COL11A1 expression. Cell Death Dis. 2019;10(4):322.","journal-title":"Cell Death Dis"},{"issue":"4","key":"6508_CR336","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10238-006-0117-4","volume":"6","author":"D Ribatti","year":"2006","unstructured":"Ribatti D, Mangialardi G, Vacca A. Stephen Paget and the \u2018seed and soil\u2019 theory of metastatic dissemination. Clin Exp Med. 2006;6(4):145\u20139.","journal-title":"Clin Exp Med"},{"issue":"4","key":"6508_CR337","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s13402-020-00513-9","volume":"43","author":"M Yousefi","year":"2020","unstructured":"Yousefi M, Dehghani S, Nosrati R, Ghanei M, Salmaninejad A, Rajaie S, Hasanzadeh M, Pasdar A. Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles. Cell Oncol (Dordr). 2020;43(4):515\u201338.","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"6508_CR338","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s42003-020-01246-z","volume":"3","author":"V Krishnan","year":"2020","unstructured":"Krishnan V, Tallapragada S, Schaar B, Kamat K, Chanana AM, Zhang Y, Patel S, Parkash V, Rinker-Schaeffer C, Folkins AK, et al. Omental macrophages secrete chemokine ligands that promote ovarian cancer colonization of the omentum via CCR1. Commun Biol. 2020;3(1):524.","journal-title":"Commun Biol"},{"issue":"12","key":"6508_CR339","doi-asserted-by":"publisher","first-page":"21436","DOI":"10.1002\/jcp.28776","volume":"234","author":"YX Wang","year":"2019","unstructured":"Wang YX, Zhu N, Zhang CJ, Wang YK, Wu HT, Li Q, Du K, Liao DF, Qin L. Friend or foe: multiple roles of adipose tissue in cancer formation and progression. J Cell Physiol. 2019;234(12):21436\u201349.","journal-title":"J Cell Physiol"},{"issue":"1","key":"6508_CR340","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1038\/s41467-020-20140-0","volume":"11","author":"M Song","year":"2020","unstructured":"Song M, Yeku OO, Rafiq S, Purdon T, Dong X, Zhu L, Zhang T, Wang H, Yu Z, Mai J, et al. Tumor derived UBR5 promotes ovarian cancer growth and metastasis through inducing immunosuppressive macrophages. Nat Commun. 2020;11(1):6298.","journal-title":"Nat Commun"},{"key":"6508_CR341","doi-asserted-by":"crossref","unstructured":"Long L, Hu Y, Long T, Lu X, Tuo Y, Li Y, Ke Z. Tumor-associated macrophages induced spheroid formation by CCL18-ZEB1-M-CSF feedback loop to promote transcoelomic metastasis of ovarian cancer. J Immunother Cancer 2021, 9(12).","DOI":"10.1136\/jitc-2021-003973"},{"issue":"2","key":"6508_CR342","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/mc.22750","volume":"57","author":"U Cho","year":"2018","unstructured":"Cho U, Kim B, Kim S, Han Y, Song YS. Pro-inflammatory M1 macrophage enhances metastatic potential of ovarian cancer cells through NF-kappaB activation. Mol Carcinog. 2018;57(2):235\u201342.","journal-title":"Mol Carcinog"},{"issue":"16","key":"6508_CR343","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1038\/s41388-018-0637-x","volume":"38","author":"T Motohara","year":"2019","unstructured":"Motohara T, Masuda K, Morotti M, Zheng Y, El-Sahhar S, Chong KY, Wietek N, Alsaadi A, Carrami EM, Hu Z, et al. An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene. 2019;38(16):2885\u201398.","journal-title":"Oncogene"},{"issue":"13","key":"6508_CR344","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1158\/0008-5472.CAN-17-3341","volume":"78","author":"MJ Carroll","year":"2018","unstructured":"Carroll MJ, Fogg KC, Patel HA, Krause HB, Mancha AS, Patankar MS, Weisman PS, Barroilhet L, Kreeger PK. Alternatively-Activated macrophages upregulate mesothelial expression of P-Selectin to enhance adhesion of ovarian Cancer cells. Cancer Res. 2018;78(13):3560\u201373.","journal-title":"Cancer Res"},{"issue":"1","key":"6508_CR345","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.canlet.2012.07.020","volume":"326","author":"M Castells","year":"2012","unstructured":"Castells M, Thibault B, Mery E, Golzio M, Pasquet M, Hennebelle I, Bourin P, Mirshahi M, Delord JP, Querleu D, et al. Ovarian ascites-derived hospicells promote angiogenesis via activation of macrophages. Cancer Lett. 2012;326(1):59\u201368.","journal-title":"Cancer Lett"},{"issue":"4","key":"6508_CR346","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41419-020-2438-8","volume":"11","author":"AM Steitz","year":"2020","unstructured":"Steitz AM, Steffes A, Finkernagel F, Unger A, Sommerfeld L, Jansen JM, Wagner U, Graumann J, Muller R, Reinartz S. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and Tenascin C. Cell Death Dis. 2020;11(4):249.","journal-title":"Cell Death Dis"},{"key":"6508_CR347","doi-asserted-by":"publisher","first-page":"1045957","DOI":"10.3389\/fimmu.2022.1045957","volume":"13","author":"Y Xu","year":"2022","unstructured":"Xu Y, Zuo F, Wang H, Jing J, He X. The current landscape of predictive and prognostic biomarkers for immune checkpoint Blockade in ovarian cancer. Front Immunol. 2022;13:1045957.","journal-title":"Front Immunol"},{"key":"6508_CR348","doi-asserted-by":"crossref","unstructured":"Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman GJ, Anthony RM et al. In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. Sci Transl Med 2017, 9(389).","DOI":"10.1126\/scitranslmed.aal3604"},{"issue":"5","key":"6508_CR349","doi-asserted-by":"publisher","first-page":"e1424672","DOI":"10.1080\/2162402X.2018.1424672","volume":"7","author":"S Lieber","year":"2018","unstructured":"Lieber S, Reinartz S, Raifer H, Finkernagel F, Dreyer T, Bronger H, Jansen JM, Wagner U, Worzfeld T, Muller R, et al. Prognosis of ovarian cancer is associated with effector memory CD8(+) T cell accumulation in Ascites, CXCL9 levels and activation-triggered signal transduction in T cells. Oncoimmunology. 2018;7(5):e1424672.","journal-title":"Oncoimmunology"},{"issue":"1","key":"6508_CR350","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13059-018-1412-6","volume":"19","author":"L Zhao","year":"2018","unstructured":"Zhao L, Wang W, Huang S, Yang Z, Xu L, Yang Q, Zhou X, Wang J, Shen Q, Wang C, et al. The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive Immunomodulatory transcripts. Genome Biol. 2018;19(1):35.","journal-title":"Genome Biol"},{"issue":"1","key":"6508_CR351","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1084\/jem.20181170","volume":"216","author":"W Lee","year":"2019","unstructured":"Lee W, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora H. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019;216(1):176\u201394.","journal-title":"J Exp Med"},{"issue":"1","key":"6508_CR352","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12885-019-5326-9","volume":"19","author":"O Abu-Shawer","year":"2019","unstructured":"Abu-Shawer O, Abu-Shawer M, Hirmas N, Alhouri A, Massad A, Alsibai B, Sultan H, Hammo H, Souleiman M, Shebli Y, et al. Hematologic markers of distant metastases and poor prognosis in gynecological cancers. BMC Cancer. 2019;19(1):141.","journal-title":"BMC Cancer"},{"issue":"1","key":"6508_CR353","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/s41467-020-15186-z","volume":"11","author":"S Mabuchi","year":"2020","unstructured":"Mabuchi S, Komura N, Sasano T, Shimura K, Yokoi E, Kozasa K, Kuroda H, Takahashi R, Kawano M, Matsumoto Y, et al. Pretreatment tumor-related leukocytosis misleads positron emission tomography-computed tomography during lymph node staging in gynecological malignancies. Nat Commun. 2020;11(1):1364.","journal-title":"Nat Commun"},{"issue":"3","key":"6508_CR354","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.immuni.2013.08.025","volume":"39","author":"TX Cui","year":"2013","unstructured":"Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, Vatan L, Szeliga W, Mao Y, Thomas DG, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity. 2013;39(3):611\u201321.","journal-title":"Immunity"},{"issue":"24","key":"6508_CR355","doi-asserted-by":"publisher","first-page":"7106","DOI":"10.1158\/0008-5472.CAN-16-1456","volume":"76","author":"A Metelli","year":"2016","unstructured":"Metelli A, Wu BX, Fugle CW, Rachidi S, Sun S, Zhang Y, Wu J, Tomlinson S, Howe PH, Yang Y, et al. Surface expression of TGFbeta Docking receptor GARP promotes oncogenesis and immune tolerance in breast Cancer. Cancer Res. 2016;76(24):7106\u201317.","journal-title":"Cancer Res"},{"key":"6508_CR356","doi-asserted-by":"crossref","unstructured":"Waldmann TA. Cytokines in Cancer immunotherapy. Cold Spring Harb Perspect Biol 2018, 10(12).","DOI":"10.1101\/cshperspect.a028472"},{"key":"6508_CR357","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12885-015-1511-7","volume":"15","author":"D Lane","year":"2015","unstructured":"Lane D, Matte I, Garde-Granger P, Laplante C, Carignan A, Rancourt C, Piche A. Inflammation-regulating factors in Ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers. BMC Cancer. 2015;15:492.","journal-title":"BMC Cancer"},{"key":"6508_CR358","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1749-6632.2000.tb06550.x","volume":"905","author":"X Fang","year":"2000","unstructured":"Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, et al. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci. 2000;905:188\u2013208.","journal-title":"Ann N Y Acad Sci"},{"key":"6508_CR359","doi-asserted-by":"publisher","first-page":"1159061","DOI":"10.3389\/fimmu.2023.1159061","volume":"14","author":"X Fu","year":"2023","unstructured":"Fu X, Wang Q, Du H, Hao H. CXCL8 and the peritoneal metastasis of ovarian and gastric cancer. Front Immunol. 2023;14:1159061.","journal-title":"Front Immunol"},{"issue":"17","key":"6508_CR360","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1038\/s41388-017-0093-z","volume":"37","author":"A Ladanyi","year":"2018","unstructured":"Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018;37(17):2285\u2013301.","journal-title":"Oncogene"},{"issue":"2","key":"6508_CR361","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4143\/crt.2016.175","volume":"49","author":"B Kim","year":"2017","unstructured":"Kim B, Kim HS, Kim S, Haegeman G, Tsang BK, Dhanasekaran DN, Song YS. Adipose stromal cells from visceral and subcutaneous fat facilitate migration of ovarian Cancer cells via IL-6\/JAK2\/STAT3 pathway. Cancer Res Treat. 2017;49(2):338\u201349.","journal-title":"Cancer Res Treat"},{"issue":"1","key":"6508_CR362","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/sj.bjc.6604794","volume":"100","author":"M Colomiere","year":"2009","unstructured":"Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, Ackland L, Ahmed N. Cross talk of signals between EGFR and IL-6R through JAK2\/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer. 2009;100(1):134\u201344.","journal-title":"Br J Cancer"},{"issue":"1","key":"6508_CR363","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.molonc.2015.06.004","volume":"10","author":"X Tong","year":"2016","unstructured":"Tong X, Barbour M, Hou K, Gao C, Cao S, Zheng J, Zhao Y, Mu R, Jiang HR. Interleukin-33 predicts poor prognosis and promotes ovarian cancer cell growth and metastasis through regulating ERK and JNK signaling pathways. Mol Oncol. 2016;10(1):113\u201325.","journal-title":"Mol Oncol"},{"issue":"8","key":"6508_CR364","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/s41388-019-1090-1","volume":"39","author":"C Sun","year":"2020","unstructured":"Sun C, Li X, Guo E, Li N, Zhou B, Lu H, Huang J, Xia M, Shan W, Wang B, et al. MCP-1\/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis. Oncogene. 2020;39(8):1681\u201395.","journal-title":"Oncogene"},{"issue":"11","key":"6508_CR365","first-page":"4785","volume":"33","author":"S Furukawa","year":"2013","unstructured":"Furukawa S, Soeda S, Kiko Y, Suzuki O, Hashimoto Y, Watanabe T, Nishiyama H, Tasaki K, Hojo H, Abe M, et al. MCP-1 promotes invasion and adhesion of human ovarian cancer cells. Anticancer Res. 2013;33(11):4785\u201390.","journal-title":"Anticancer Res"},{"issue":"21","key":"6508_CR366","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1038\/s41388-020-1288-2","volume":"39","author":"T Kan","year":"2020","unstructured":"Kan T, Wang W, Ip PP, Zhou S, Wong AS, Wang X, Yang M. Single-cell EMT-related transcriptional analysis revealed intra-cluster heterogeneity of tumor cell clusters in epithelial ovarian cancer Ascites. Oncogene. 2020;39(21):4227\u201340.","journal-title":"Oncogene"},{"key":"6508_CR367","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3389\/fonc.2012.00033","volume":"2","author":"B Davidson","year":"2012","unstructured":"Davidson B, Trope CG, Reich R. Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol. 2012;2:33.","journal-title":"Front Oncol"},{"key":"6508_CR368","doi-asserted-by":"crossref","unstructured":"Loh CY, Chai JY, Tang TF, Wong WF, Sethi G, Shanmugam MK, Chong PP, Looi CY. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells 2019, 8(10).","DOI":"10.3390\/cells8101118"},{"issue":"9","key":"6508_CR369","doi-asserted-by":"publisher","first-page":"e0184439","DOI":"10.1371\/journal.pone.0184439","volume":"12","author":"M Rosso","year":"2017","unstructured":"Rosso M, Majem B, Devis L, Lapyckyj L, Besso MJ, Llaurado M, Abascal MF, Matos ML, Lanau L, Castellvi J, et al. E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness. PLoS ONE. 2017;12(9):e0184439.","journal-title":"PLoS ONE"},{"issue":"46","key":"6508_CR370","doi-asserted-by":"publisher","first-page":"81052","DOI":"10.18632\/oncotarget.18898","volume":"8","author":"C Dai","year":"2017","unstructured":"Dai C, Cao J, Zeng Y, Xu S, Jia X, Xu P. E-cadherin expression as a prognostic factor in patients with ovarian cancer: a meta-analysis. Oncotarget. 2017;8(46):81052\u201361.","journal-title":"Oncotarget"},{"issue":"1","key":"6508_CR371","doi-asserted-by":"publisher","first-page":"16633","DOI":"10.1038\/s41598-018-34747-3","volume":"8","author":"TTA Liguori","year":"2018","unstructured":"Liguori TTA, Liguori GR, Moreira LFP, Harmsen MC. Fibroblast growth factor-2, but not the adipose tissue-derived stromal cells secretome, inhibits TGF-beta1-induced differentiation of human cardiac fibroblasts into myofibroblasts. Sci Rep. 2018;8(1):16633.","journal-title":"Sci Rep"},{"issue":"10","key":"6508_CR372","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s00125-012-2629-7","volume":"55","author":"V D\u2019Esposito","year":"2012","unstructured":"D\u2019Esposito V, Passaretti F, Hammarstedt A, Liguoro D, Terracciano D, Molea G, Canta L, Miele C, Smith U, Beguinot F, et al. Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia. 2012;55(10):2811\u201322.","journal-title":"Diabetologia"},{"issue":"4","key":"6508_CR373","doi-asserted-by":"publisher","first-page":"E843","DOI":"10.1152\/ajpendo.00174.2006","volume":"291","author":"LN Bell","year":"2006","unstructured":"Bell LN, Ward JL, Degawa-Yamauchi M, Bovenkerk JE, Jones R, Cacucci BM, Gupta CE, Sheridan C, Sheridan K, Shankar SS, et al. Adipose tissue production of hepatocyte growth factor contributes to elevated serum HGF in obesity. Am J Physiol Endocrinol Metab. 2006;291(4):E843\u2013848.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"6508_CR374","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12935-015-0263-4","volume":"15","author":"DL Bourgeois","year":"2015","unstructured":"Bourgeois DL, Kabarowski KA, Porubsky VL, Kreeger PK. High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation. Cancer Cell Int. 2015;15:112.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"6508_CR375","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<476::AID-IJC7>3.0.CO;2-V","volume":"83","author":"HM Sowter","year":"1999","unstructured":"Sowter HM, Corps AN, Smith SK. Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. Int J Cancer. 1999;83(4):476\u201380.","journal-title":"Int J Cancer"},{"issue":"2","key":"6508_CR376","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.canlet.2012.08.016","volume":"326","author":"MT Lau","year":"2012","unstructured":"Lau MT, Leung PC. The PI3K\/Akt\/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Cancer Lett. 2012;326(2):191\u20138.","journal-title":"Cancer Lett"},{"issue":"3","key":"6508_CR377","doi-asserted-by":"publisher","first-page":"e59083","DOI":"10.1371\/journal.pone.0059083","volume":"8","author":"MT Lau","year":"2013","unstructured":"Lau MT, So WK, Leung PC. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K\/Akt\/mTOR and MAPK\/ERK signaling in ovarian cancer cells. PLoS ONE. 2013;8(3):e59083.","journal-title":"PLoS ONE"},{"issue":"11","key":"6508_CR378","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1177\/1933719116648214","volume":"23","author":"M Hoffmann","year":"2016","unstructured":"Hoffmann M, Fiedor E, Ptak A. 17beta-Estradiol reverses Leptin-Inducing ovarian Cancer cell migration by the PI3K\/Akt signaling pathway. Reprod Sci. 2016;23(11):1600\u20138.","journal-title":"Reprod Sci"},{"issue":"2","key":"6508_CR379","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1002\/jcb.26396","volume":"119","author":"A Ghasemi","year":"2018","unstructured":"Ghasemi A, Hashemy SI, Aghaei M, Panjehpour M. Leptin induces matrix metalloproteinase 7 expression to promote ovarian cancer cell invasion by activating ERK and JNK pathways. J Cell Biochem. 2018;119(2):2333\u201344.","journal-title":"J Cell Biochem"},{"issue":"8","key":"6508_CR380","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1541-7786.MCR-05-0232","volume":"4","author":"N Muthukumaran","year":"2006","unstructured":"Muthukumaran N, Miletti-Gonzalez KE, Ravindranath AK, Rodriguez-Rodriguez L. Tumor necrosis factor-alpha differentially modulates CD44 expression in ovarian cancer cells. Mol Cancer Res. 2006;4(8):511\u201320.","journal-title":"Mol Cancer Res"},{"key":"6508_CR381","doi-asserted-by":"publisher","first-page":"589601","DOI":"10.3389\/fonc.2020.589601","volume":"10","author":"A Martincuks","year":"2020","unstructured":"Martincuks A, Li PC, Zhao Q, Zhang C, Li YJ, Yu H, Rodriguez-Rodriguez L. CD44 in ovarian Cancer progression and therapy Resistance-A critical role for STAT3. Front Oncol. 2020;10:589601.","journal-title":"Front Oncol"},{"issue":"Pt B","key":"6508_CR382","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.mce.2017.02.002","volume":"462","author":"S Guaita-Esteruelas","year":"2018","unstructured":"Guaita-Esteruelas S, Guma J, Masana L, Borras J. The peritumoural adipose tissue microenvironment and cancer. The roles of fatty acid binding protein 4 and fatty acid binding protein 5. Mol Cell Endocrinol. 2018;462(Pt B):107\u201318.","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"6508_CR383","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1440-1827.2006.01982.x","volume":"56","author":"S Ohira","year":"2006","unstructured":"Ohira S, Itatsu K, Sasaki M, Harada K, Sato Y, Zen Y, Ishikawa A, Oda K, Nagasaka T, Nimura Y, et al. Local balance of transforming growth factor-beta1 secreted from cholangiocarcinoma cells and stromal-derived factor-1 secreted from stromal fibroblasts is a factor involved in invasion of cholangiocarcinoma. Pathol Int. 2006;56(7):381\u20139.","journal-title":"Pathol Int"},{"issue":"4","key":"6508_CR384","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ijc.24040","volume":"124","author":"Y Matsuo","year":"2009","unstructured":"Matsuo Y, Ochi N, Sawai H, Yasuda A, Takahashi H, Funahashi H, Takeyama H, Tong Z, Guha S. CXCL8\/IL-8 and CXCL12\/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer. 2009;124(4):853\u201361.","journal-title":"Int J Cancer"},{"issue":"24","key":"6508_CR385","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1038\/onc.2016.487","volume":"36","author":"L Zhao","year":"2017","unstructured":"Zhao L, Ji G, Le X, Luo Z, Wang C, Feng M, Xu L, Zhang Y, Lau WB, Lau B, et al. An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis. Oncogene. 2017;36(24):3384\u201396.","journal-title":"Oncogene"},{"key":"6508_CR386","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1038\/ncomms6092","volume":"5","author":"CS Leung","year":"2014","unstructured":"Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, et al. Calcium-dependent FAK\/CREB\/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun. 2014;5:5092.","journal-title":"Nat Commun"},{"issue":"3","key":"6508_CR387","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1084\/jem.20180765","volume":"216","author":"Q Gao","year":"2019","unstructured":"Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, Liu Y, Zhou X, Zhang T, Gong C, et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med. 2019;216(3):688\u2013703.","journal-title":"J Exp Med"},{"issue":"3","key":"6508_CR388","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.yexmp.2009.09.001","volume":"87","author":"H Chen","year":"2009","unstructured":"Chen H, Yang WW, Wen QT, Xu L, Chen M. TGF-beta induces fibroblast activation protein expression; fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910PM [corrected]. Exp Mol Pathol. 2009;87(3):189\u201394.","journal-title":"Exp Mol Pathol"},{"issue":"3","key":"6508_CR389","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41388-023-02884-3","volume":"43","author":"FA Akinjiyan","year":"2024","unstructured":"Akinjiyan FA, Ibitoye Z, Zhao P, Shriver LP, Patti GJ, Longmore GD, Fuh KC. DDR2-regulated arginase activity in ovarian cancer-associated fibroblasts promotes collagen production and tumor progression. Oncogene. 2024;43(3):189\u2013201.","journal-title":"Oncogene"},{"issue":"5","key":"6508_CR390","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3892\/ol.2022.13278","volume":"23","author":"C Feng","year":"2022","unstructured":"Feng C, Kou L, Yin P, Jing Y. Excessive activation of IL-33\/ST2 in cancer-associated fibroblasts promotes invasion and metastasis in ovarian cancer. Oncol Lett. 2022;23(5):158.","journal-title":"Oncol Lett"},{"key":"6508_CR391","doi-asserted-by":"crossref","unstructured":"Kim MJ, Jung D, Park JY, Lee SM, An HJ. GLIS1 in Cancer-Associated fibroblasts regulates the migration and invasion of ovarian Cancer cells. Int J Mol Sci 2022, 23(4).","DOI":"10.3390\/ijms23042218"},{"issue":"5","key":"6508_CR392","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1593\/neo.101720","volume":"13","author":"IG Schauer","year":"2011","unstructured":"Schauer IG, Sood AK, Mok S, Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia. 2011;13(5):393\u2013405.","journal-title":"Neoplasia"},{"issue":"Suppl 1","key":"6508_CR393","doi-asserted-by":"publisher","first-page":"i33","DOI":"10.1093\/annonc\/mdw093","volume":"27","author":"BJ Monk","year":"2016","unstructured":"Monk BJ, Minion LE, Coleman RL. Anti-angiogenic agents in ovarian cancer: past, present, and future. Ann Oncol. 2016;27(Suppl 1):i33\u20139.","journal-title":"Ann Oncol"},{"issue":"1","key":"6508_CR394","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0022-4804(03)00307-X","volume":"115","author":"A Sako","year":"2003","unstructured":"Sako A, Kitayama J, Yamaguchi H, Kaisaki S, Suzuki H, Fukatsu K, Fujii S, Nagawa H. Vascular endothelial growth factor synthesis by human omental mesothelial cells is augmented by fibroblast growth factor-2: possible role of mesothelial cell on the development of peritoneal metastasis. J Surg Res. 2003;115(1):113\u201320.","journal-title":"J Surg Res"},{"issue":"1","key":"6508_CR395","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10585-015-9753-y","volume":"33","author":"J Mikula-Pietrasik","year":"2016","unstructured":"Mikula-Pietrasik J, Sosinska P, Naumowicz E, Maksin K, Piotrowska H, Wozniak A, Szpurek D, Ksiazek K. Senescent peritoneal mesothelium induces a pro-angiogenic phenotype in ovarian cancer cells in vitro and in a mouse xenograft model in vivo. Clin Exp Metastasis. 2016;33(1):15\u201327.","journal-title":"Clin Exp Metastasis"},{"key":"6508_CR396","doi-asserted-by":"crossref","unstructured":"Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan DM, Poggi A, Bruno A, Mortara L. The ovarian Cancer tumor immune microenvironment (TIME) as target for therapy: A focus on innate immunity cells as therapeutic effectors. Int J Mol Sci 2020, 21(9).","DOI":"10.3390\/ijms21093125"},{"issue":"15","key":"6508_CR397","first-page":"5721","volume":"9","author":"AT Byrne","year":"2003","unstructured":"Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, Jaffe RB. Vascular endothelial growth factor-trap decreases tumor burden, inhibits Ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 2003;9(15):5721\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6508_CR398","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1186\/s12885-019-5757-3","volume":"19","author":"M Sopo","year":"2019","unstructured":"Sopo M, Anttila M, Hamalainen K, Kivela A, Yla-Herttuala S, Kosma VM, Keski-Nisula L, Sallinen H. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer. BMC Cancer. 2019;19(1):584.","journal-title":"BMC Cancer"},{"issue":"4","key":"6508_CR399","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ijc.26094","volume":"130","author":"AC Ziogas","year":"2012","unstructured":"Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. Int J Cancer. 2012;130(4):857\u201364.","journal-title":"Int J Cancer"},{"issue":"2","key":"6508_CR400","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s10585-021-10077-z","volume":"38","author":"A Kumari","year":"2021","unstructured":"Kumari A, Shonibare Z, Monavarian M, Arend RC, Lee NY, Inman GJ, Mythreye K. TGFbeta signaling networks in ovarian cancer progression and plasticity. Clin Exp Metastasis. 2021;38(2):139\u201361.","journal-title":"Clin Exp Metastasis"},{"key":"6508_CR401","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cca.2018.03.019","volume":"482","author":"V Dalal","year":"2018","unstructured":"Dalal V, Kumar R, Kumar S, Sharma A, Kumar L, Sharma JB, Roy KK, Singh N, Vanamail P. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients. Clin Chim Acta. 2018;482:27\u201332.","journal-title":"Clin Chim Acta"},{"issue":"1","key":"6508_CR402","first-page":"89","volume":"10","author":"H Yabushita","year":"2003","unstructured":"Yabushita H, Shimazu M, Noguchi M, Kishida T, Narumiya H, Sawaguchi K, Noguchi M. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncol Rep. 2003;10(1):89\u201395.","journal-title":"Oncol Rep"},{"issue":"17","key":"6508_CR403","first-page":"5224","volume":"63","author":"D Belotti","year":"2003","unstructured":"Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for Ascites formation. Cancer Res. 2003;63(17):5224\u20139.","journal-title":"Cancer Res"},{"issue":"4","key":"6508_CR404","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1158\/1541-7786.MCR-07-0366","volume":"6","author":"D Belotti","year":"2008","unstructured":"Belotti D, Calcagno C, Garofalo A, Caronia D, Riccardi E, Giavazzi R, Taraboletti G. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res. 2008;6(4):525\u201334.","journal-title":"Mol Cancer Res"},{"issue":"5","key":"6508_CR405","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3892\/ijo.2017.3957","volume":"50","author":"J Yang","year":"2017","unstructured":"Yang J, Wang Y, Zeng Z, Qiao L, Zhuang L, Gao Q, Ma D, Huang X. Smad4 deletion in blood vessel endothelial cells promotes ovarian cancer metastasis. Int J Oncol. 2017;50(5):1693\u2013700.","journal-title":"Int J Oncol"},{"key":"6508_CR406","doi-asserted-by":"crossref","unstructured":"Yin M, Zhou HJ, Zhang J, Lin C, Li H, Li X, Li Y, Zhang H, Breckenridge DG, Ji W et al. ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis. JCI Insight 2017, 2(18).","DOI":"10.1172\/jci.insight.91828"},{"issue":"3","key":"6508_CR407","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ccell.2017.01.007","volume":"31","author":"E Wieland","year":"2017","unstructured":"Wieland E, Rodriguez-Vita J, Liebler SS, Mogler C, Moll I, Herberich SE, Espinet E, Herpel E, Menuchin A, Chang-Claude J, et al. Endothelial Notch1 activity facilitates metastasis. Cancer Cell. 2017;31(3):355\u201367.","journal-title":"Cancer Cell"},{"issue":"7","key":"6508_CR408","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","volume":"18","author":"AN Brooks","year":"2012","unstructured":"Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res. 2012;18(7):1855\u201362.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6508_CR409","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1078-0432.CCR-12-2736","volume":"19","author":"TM Zaid","year":"2013","unstructured":"Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, et al. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013;19(4):809\u201320.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"6508_CR410","doi-asserted-by":"publisher","first-page":"4614","DOI":"10.1172\/JCI74778","volume":"124","author":"HA Kenny","year":"2014","unstructured":"Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014;124(10):4614\u201328.","journal-title":"J Clin Invest"},{"key":"6508_CR411","doi-asserted-by":"crossref","unstructured":"Pascual-Anton L, Cardenes B, de la Sainz R, Gonzalez-Cortijo L, Lopez-Cabrera M, Cabanas C, Sandoval P. Mesothelial-to-Mesenchymal transition and exosomes in peritoneal metastasis of ovarian Cancer. Int J Mol Sci 2021, 22(21).","DOI":"10.3390\/ijms222111496"},{"issue":"1","key":"6508_CR412","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1038\/s41467-020-17383-2","volume":"11","author":"CL Au-Yeung","year":"2020","unstructured":"Au-Yeung CL, Yeung TL, Achreja A, Zhao H, Yip KP, Kwan SY, Onstad M, Sheng J, Zhu Y, Baluya DL, et al. ITLN1 modulates invasive potential and metabolic reprogramming of ovarian cancer cells in omental microenvironment. Nat Commun. 2020;11(1):3546.","journal-title":"Nat Commun"},{"issue":"2","key":"6508_CR413","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41389-020-0209-0","volume":"9","author":"MKY Siu","year":"2020","unstructured":"Siu MKY, Jiang YX, Wang JJ, Leung THY, Ngu SF, Cheung ANY, Ngan HYS, Chan KKL. PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial adhesion, invasion, and angiogenesis via alpha5beta1 integrin and JNK\/IL-8 signaling. Oncogenesis. 2020;9(2):24.","journal-title":"Oncogenesis"},{"issue":"21","key":"6508_CR414","doi-asserted-by":"publisher","first-page":"6735","DOI":"10.1158\/1078-0432.CCR-07-4843","volume":"14","author":"DJ Waugh","year":"2008","unstructured":"Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res. 2008;14(21):6735\u201341.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"6508_CR415","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/0008-5472.CAN-19-1601","volume":"80","author":"M Asem","year":"2020","unstructured":"Asem M, Young AM, Oyama C, De La Claure A, Liu Y, Yang J, Hilliard TS, Johnson J, Harper EI, Guldner I, et al. Host Wnt5a potentiates microenvironmental regulation of ovarian Cancer metastasis. Cancer Res. 2020;80(5):1156\u201370.","journal-title":"Cancer Res"},{"issue":"2","key":"6508_CR416","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/path.4889","volume":"242","author":"A Rynne-Vidal","year":"2017","unstructured":"Rynne-Vidal A, Au-Yeung CL, Jimenez-Heffernan JA, Perez-Lozano ML, Cremades-Jimeno L, Barcena C, Cristobal-Garcia I, Fernandez-Chacon C, Yeung TL, Mok SC, et al. Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer. J Pathol. 2017;242(2):140\u201351.","journal-title":"J Pathol"},{"issue":"1","key":"6508_CR417","first-page":"193","volume":"39","author":"K Fujikake","year":"2018","unstructured":"Fujikake K, Kajiyama H, Yoshihara M, Nishino K, Yoshikawa N, Utsumi F, Suzuki S, Niimi K, Sakata J, Mitsui H, et al. A novel mechanism of neovascularization in peritoneal dissemination via cancer-associated mesothelial cells affected by TGF-beta derived from ovarian cancer. Oncol Rep. 2018;39(1):193\u2013200.","journal-title":"Oncol Rep"},{"key":"6508_CR418","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.canlet.2018.10.027","volume":"442","author":"Y Peng","year":"2019","unstructured":"Peng Y, Kajiyama H, Yuan H, Nakamura K, Yoshihara M, Yokoi A, Fujikake K, Yasui H, Yoshikawa N, Suzuki S, et al. PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination. Cancer Lett. 2019;442:181\u201392.","journal-title":"Cancer Lett"},{"issue":"8","key":"6508_CR419","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.ajpath.2015.04.004","volume":"185","author":"D Haria","year":"2015","unstructured":"Haria D, Trinh BQ, Ko SY, Barengo N, Liu J, Naora H. The Homeoprotein DLX4 stimulates NF-kappaB activation and CD44-mediated tumor-mesothelial cell interactions in ovarian cancer. Am J Pathol. 2015;185(8):2298\u2013308.","journal-title":"Am J Pathol"},{"key":"6508_CR420","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.semcancer.2020.11.021","volume":"81","author":"K Ksiazek","year":"2022","unstructured":"Ksiazek K. Where does cellular senescence belong in the pathophysiology of ovarian cancer? Semin Cancer Biol. 2022;81:14\u201323.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"6508_CR421","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.2353\/ajpath.2009.080613","volume":"174","author":"K Ksiazek","year":"2009","unstructured":"Ksiazek K, Mikula-Pietrasik J, Korybalska K, Dworacki G, Jorres A, Witowski J. Senescent peritoneal mesothelial cells promote ovarian cancer cell adhesion: the role of oxidative stress-induced fibronectin. Am J Pathol. 2009;174(4):1230\u201340.","journal-title":"Am J Pathol"},{"issue":"2","key":"6508_CR422","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/carcin\/bgz083","volume":"41","author":"H Tang","year":"2020","unstructured":"Tang H, Chu Y, Huang Z, Cai J, Wang Z. The metastatic phenotype shift toward myofibroblast of adipose-derived mesenchymal stem cells promotes ovarian cancer progression. Carcinogenesis. 2020;41(2):182\u201393.","journal-title":"Carcinogenesis"},{"key":"6508_CR423","doi-asserted-by":"crossref","unstructured":"Zhao G, Cardenas H, Matei D. Ovarian Cancer-Why lipids matter. Cancers (Basel) 2019, 11(12).","DOI":"10.3390\/cancers11121870"},{"issue":"8","key":"6508_CR424","doi-asserted-by":"publisher","first-page":"114551","DOI":"10.1016\/j.celrep.2024.114551","volume":"43","author":"L Frisbie","year":"2024","unstructured":"Frisbie L, Pressimone C, Dyer E, Baruwal R, Garcia G, St Croix C, Watkins S, Calderone M, Gorecki G, Javed Z, et al. Carcinoma-associated mesenchymal stem cells promote ovarian cancer heterogeneity and metastasis through mitochondrial transfer. Cell Rep. 2024;43(8):114551.","journal-title":"Cell Rep"},{"issue":"2","key":"6508_CR425","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41419-021-03490-5","volume":"12","author":"J Cai","year":"2021","unstructured":"Cai J, Gong L, Li G, Guo J, Yi X, Wang Z. Exosomes in ovarian cancer Ascites promote epithelial-mesenchymal transition of ovarian cancer cells by delivery of miR-6780b-5p. Cell Death Dis. 2021;12(2):210.","journal-title":"Cell Death Dis"},{"issue":"1","key":"6508_CR426","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12967-021-02985-1","volume":"19","author":"L Yin","year":"2021","unstructured":"Yin L, Liu X, Shao X, Feng T, Xu J, Wang Q, Hua S. The role of exosomes in lung cancer metastasis and clinical applications: an updated review. J Transl Med. 2021;19(1):312.","journal-title":"J Transl Med"},{"issue":"1","key":"6508_CR427","first-page":"13","volume":"25","author":"C Giesta","year":"1968","unstructured":"Giesta C. [Therapeutic orientation in bone tumors]. Rev Bras Med. 1968;25(1):13\u201320.","journal-title":"Rev Bras Med"},{"issue":"9","key":"6508_CR428","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/carcin\/bgu130","volume":"35","author":"O Vaksman","year":"2014","unstructured":"Vaksman O, Trope C, Davidson B, Reich R. Exosome-derived MiRNAs and ovarian carcinoma progression. Carcinogenesis. 2014;35(9):2113\u201320.","journal-title":"Carcinogenesis"},{"issue":"9","key":"6508_CR429","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/cncy.21442","volume":"122","author":"R Cappellesso","year":"2014","unstructured":"Cappellesso R, Tinazzi A, Giurici T, Simonato F, Guzzardo V, Ventura L, Crescenzi M, Chiarelli S, Fassina A. Programmed cell death 4 and MicroRNA 21 inverse expression is maintained in cells and exosomes from ovarian serous carcinoma effusions. Cancer Cytopathol. 2014;122(9):685\u201393.","journal-title":"Cancer Cytopathol"},{"issue":"1","key":"6508_CR430","doi-asserted-by":"publisher","first-page":"522","DOI":"10.3892\/or.2017.5697","volume":"38","author":"X Chen","year":"2017","unstructured":"Chen X, Ying X, Wang X, Wu X, Zhu Q, Wang X. Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization. Oncol Rep. 2017;38(1):522\u20138.","journal-title":"Oncol Rep"},{"issue":"1","key":"6508_CR431","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1186\/s12885-018-4974-5","volume":"18","author":"A Yoshimura","year":"2018","unstructured":"Yoshimura A, Sawada K, Nakamura K, Kinose Y, Nakatsuka E, Kobayashi M, Miyamoto M, Ishida K, Matsumoto Y, Kodama M, et al. Exosomal miR-99a-5p is elevated in Sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells. BMC Cancer. 2018;18(1):1065.","journal-title":"BMC Cancer"},{"issue":"1","key":"6508_CR432","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13048-025-01616-3","volume":"18","author":"L He","year":"2025","unstructured":"He L, Chen Q, Wu X. Tumour-derived Exosomal miR-205 promotes ovarian cancer cell progression through M2 macrophage polarization via the PI3K\/Akt\/mTOR pathway. J Ovarian Res. 2025;18(1):28.","journal-title":"J Ovarian Res"},{"issue":"1","key":"6508_CR433","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1158\/1541-7786.MCR-16-0191","volume":"15","author":"K Nakamura","year":"2017","unstructured":"Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Morishige KI, Kurachi H, et al. Exosomes promote ovarian Cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells. Mol Cancer Res. 2017;15(1):78\u201392.","journal-title":"Mol Cancer Res"},{"issue":"3","key":"6508_CR434","first-page":"749","volume":"25","author":"P Peng","year":"2011","unstructured":"Peng P, Yan Y, Keng S. Exosomes in the Ascites of ovarian cancer patients: origin and effects on anti-tumor immunity. Oncol Rep. 2011;25(3):749\u201362.","journal-title":"Oncol Rep"},{"key":"6508_CR435","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.canlet.2017.02.009","volume":"393","author":"Y Hu","year":"2017","unstructured":"Hu Y, Li D, Wu A, Qiu X, Di W, Huang L, Qiu L. TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via Exosomal shuttling of MicroRNA. Cancer Lett. 2017;393:60\u20137.","journal-title":"Cancer Lett"},{"issue":"7","key":"6508_CR436","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.trecan.2020.03.001","volume":"6","author":"C Attane","year":"2020","unstructured":"Attane C, Muller C. Drilling for oil: Tumor-Surrounding adipocytes fueling Cancer. Trends Cancer. 2020;6(7):593\u2013604.","journal-title":"Trends Cancer"},{"issue":"11","key":"6508_CR437","doi-asserted-by":"publisher","first-page":"T155","DOI":"10.1530\/ERC-16-0320","volume":"23","author":"C Ricciardelli","year":"2016","unstructured":"Ricciardelli C, Lokman NA, Ween MP, Oehler MK. WOMEN IN CANCER THEMATIC REVIEW: ovarian cancer-peritoneal cell interactions promote extracellular matrix processing. Endocr Relat Cancer. 2016;23(11):T155\u201368.","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"6508_CR438","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s13402-019-00486-4","volume":"43","author":"X Li","year":"2020","unstructured":"Li X, Tang M, Zhu Q, Wang X, Lin Y, Wang X. The Exosomal integrin alpha5beta1\/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration. Cell Oncol (Dordr). 2020;43(2):263\u201377.","journal-title":"Cell Oncol (Dordr)"},{"key":"6508_CR439","doi-asserted-by":"crossref","unstructured":"Huang YL, Liang CY, Ritz D, Coelho R, Septiadi D, Estermann M, Cumin C, Rimmer N, Schotzau A, Nunez Lopez M et al. Collagen-rich omentum is a premetastatic niche for integrin alpha2-mediated peritoneal metastasis. Elife 2020, 9.","DOI":"10.7554\/eLife.59442"},{"key":"6508_CR440","doi-asserted-by":"crossref","unstructured":"Langthasa J, Sarkar P, Narayanan S, Bhagat R, Vadaparty A, Bhat R. Extracellular matrix mediates moruloid-blastuloid morphodynamics in malignant ovarian spheroids. Life Sci Alliance 2021, 4(10).","DOI":"10.26508\/lsa.202000942"},{"issue":"37","key":"6508_CR441","doi-asserted-by":"publisher","first-page":"5127","DOI":"10.1038\/s41388-018-0317-x","volume":"37","author":"S Al Habyan","year":"2018","unstructured":"Al Habyan S, Kalos C, Szymborski J, McCaffrey L. Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer. Oncogene. 2018;37(37):5127\u201335.","journal-title":"Oncogene"},{"issue":"18","key":"6508_CR442","doi-asserted-by":"publisher","first-page":"25930","DOI":"10.18632\/oncotarget.8412","volume":"7","author":"Y Pan","year":"2016","unstructured":"Pan Y, Robertson G, Pedersen L, Lim E, Hernandez-Herrera A, Rowat AC, Patil SL, Chan CK, Wen Y, Zhang X, et al. miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer. Oncotarget. 2016;7(18):25930\u201348.","journal-title":"Oncotarget"},{"key":"6508_CR443","doi-asserted-by":"publisher","first-page":"577869","DOI":"10.3389\/fimmu.2020.577869","volume":"11","author":"C Yang","year":"2020","unstructured":"Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol. 2020;11:577869.","journal-title":"Front Immunol"},{"issue":"12","key":"6508_CR444","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","volume":"5","author":"JF Liu","year":"2019","unstructured":"Liu JF, Herold C, Gray KP, Penson RT, Horowitz N, Konstantinopoulos PA, Castro CM, Hill SJ, Curtis J, Luo W, et al. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: A phase 2 clinical trial. JAMA Oncol. 2019;5(12):1731\u20138.","journal-title":"JAMA Oncol"},{"key":"6508_CR445","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","volume":"71","author":"AD D\u2019Andrea","year":"2018","unstructured":"D\u2019Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst). 2018;71:172\u20136.","journal-title":"DNA Repair (Amst)"},{"issue":"22","key":"6508_CR446","doi-asserted-by":"publisher","first-page":"e1707112","DOI":"10.1002\/adma.201707112","volume":"30","author":"X Zhang","year":"2018","unstructured":"Zhang X, Wang C, Wang J, Hu Q, Langworthy B, Ye Y, Sun W, Lin J, Wang T, Fine J, et al. PD-1 Blockade cellular vesicles for Cancer immunotherapy. Adv Mater. 2018;30(22):e1707112.","journal-title":"Adv Mater"},{"issue":"27","key":"6508_CR447","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/JCO.19.00508","volume":"37","author":"LE Kandalaft","year":"2019","unstructured":"Kandalaft LE, Odunsi K, Coukos G. Immunotherapy in ovarian cancer: are we there yet?? J Clin Oncol. 2019;37(27):2460\u201371.","journal-title":"J Clin Oncol"},{"issue":"3","key":"6508_CR448","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ygyno.2018.10.008","volume":"151","author":"E Hinchcliff","year":"2018","unstructured":"Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol. 2018;151(3):407\u201313.","journal-title":"Gynecol Oncol"},{"issue":"34","key":"6508_CR449","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, et al. Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with Platinum-Resistant ovarian Cancer. J Clin Oncol. 2015;33(34):4015\u201322.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6508_CR450","doi-asserted-by":"publisher","first-page":"3914","DOI":"10.1038\/s41598-020-60738-4","volume":"10","author":"C Friese","year":"2020","unstructured":"Friese C, Harbst K, Borch TH, Westergaard MCW, Pedersen M, Kverneland A, Jonsson G, Donia M, Svane IM, Met O. CTLA-4 Blockade boosts the expansion of tumor-reactive CD8(+) tumor-infiltrating lymphocytes in ovarian cancer. Sci Rep. 2020;10(1):3914.","journal-title":"Sci Rep"},{"issue":"1","key":"6508_CR451","doi-asserted-by":"publisher","first-page":"e1249561","DOI":"10.1080\/2162402X.2016.1249561","volume":"6","author":"RY Huang","year":"2017","unstructured":"Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint Blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6(1):e1249561.","journal-title":"Oncoimmunology"},{"issue":"1","key":"6508_CR452","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ygyno.2020.09.045","volume":"160","author":"F Blanc-Durand","year":"2021","unstructured":"Blanc-Durand F, Genestie C, Galende EY, Gouy S, Morice P, Pautier P, Maulard A, Mesnage S, Le Formal A, Brizais C, et al. Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape. Gynecol Oncol. 2021;160(1):279\u201384.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"6508_CR453","doi-asserted-by":"publisher","first-page":"e12917","DOI":"10.1111\/sji.12917","volume":"92","author":"E Benard","year":"2020","unstructured":"Benard E, Casey NP, Inderberg EM, Walchli S. SJI 2020 special issue: A catalogue of ovarian Cancer targets for CAR therapy. Scand J Immunol. 2020;92(4):e12917.","journal-title":"Scand J Immunol"},{"issue":"30","key":"6508_CR454","doi-asserted-by":"publisher","first-page":"3468","DOI":"10.1200\/JCO.20.01924","volume":"38","author":"WP Tew","year":"2020","unstructured":"Tew WP, Lacchetti C, Ellis A, Maxian K, Banerjee S, Bookman M, Jones MB, Lee JM, Lheureux S, Liu JF, et al. PARP inhibitors in the management of ovarian cancer: ASCO guideline. J Clin Oncol. 2020;38(30):3468\u201393.","journal-title":"J Clin Oncol"},{"issue":"12","key":"6508_CR455","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/S1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, et al. Maintenance Olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(12):1721\u201331.","journal-title":"Lancet Oncol"},{"issue":"7","key":"6508_CR456","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","volume":"22","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021;22(7):1034\u201346.","journal-title":"Lancet Oncol"},{"issue":"17","key":"6508_CR457","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, Myers T, Taskiran C, Robison K, Maenpaa J, et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: Placebo-Controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J Clin Oncol. 2021;39(17):1842\u201355.","journal-title":"J Clin Oncol"},{"issue":"9","key":"6508_CR458","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","volume":"22","author":"BJ Monk","year":"2021","unstructured":"Monk BJ, Colombo N, Oza AM, Fujiwara K, Birrer MJ, Randall L, Poddubskaya EV, Scambia G, Shparyk YV, Lim MC, et al. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(9):1275\u201389.","journal-title":"Lancet Oncol"},{"issue":"9","key":"6508_CR459","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.2174\/0115672018253815230922070558","volume":"21","author":"P Mathur","year":"2024","unstructured":"Mathur P, Bhatt S, Kumar S, Kamboj S, Kamboj R, Rana A, Kumar H, Verma R. Deciphering the therapeutic applications of nanomedicine in ovarian Cancer therapy: an overview. Curr Drug Deliv. 2024;21(9):1180\u201396.","journal-title":"Curr Drug Deliv"},{"issue":"3\u20134","key":"6508_CR460","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1615\/CritRevOncog.2014011455","volume":"19","author":"SA Engelberth","year":"2014","unstructured":"Engelberth SA, Hempel N, Bergkvist M. Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics. Crit Rev Oncog. 2014;19(3\u20134):281\u2013315.","journal-title":"Crit Rev Oncog"},{"issue":"1","key":"6508_CR461","doi-asserted-by":"publisher","first-page":"e000573","DOI":"10.1136\/bmjonc-2024-000573","volume":"4","author":"AA Gabizon","year":"2025","unstructured":"Gabizon AA, Gabizon-Peretz S, Modaresahmadi S, La-Beck NM. Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil\/Caelyx): an updated analysis and future perspective. BMJ Oncol. 2025;4(1):e000573.","journal-title":"BMJ Oncol"},{"issue":"5","key":"6508_CR462","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2174\/138955712800493924","volume":"12","author":"C Luo","year":"2012","unstructured":"Luo C, Wang Y, Chen Q, Han X, Liu X, Sun J, He Z. Advances of Paclitaxel formulations based on nanosystem delivery technology. Mini Rev Med Chem. 2012;12(5):434\u201344.","journal-title":"Mini Rev Med Chem"},{"issue":"1\u20132","key":"6508_CR463","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1\u20132):271\u201384.","journal-title":"J Control Release"},{"key":"6508_CR464","doi-asserted-by":"publisher","first-page":"122827","DOI":"10.1016\/j.ijpharm.2023.122827","volume":"636","author":"Y Huang","year":"2023","unstructured":"Huang Y, Li C, Zhang X, Zhang M, Ma Y, Qin D, Tang S, Fei W, Qin J. Nanotechnology-integrated ovarian cancer metastasis therapy: insights from the metastatic mechanisms into administration routes and therapy strategies. Int J Pharm. 2023;636:122827.","journal-title":"Int J Pharm"},{"key":"6508_CR465","doi-asserted-by":"crossref","unstructured":"Gomez S, Cox OL, Walker RR 3rd, Rentia U, Hadley M, Arthofer E, Diab N, Grundy EE, Kanholm T, McDonald JI et al. Inhibiting DNA methylation and RNA editing upregulates Immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer. J Immunother Cancer 2022, 10(11).","DOI":"10.1136\/jitc-2022-004974"},{"issue":"8","key":"6508_CR466","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1038\/bjc.2014.116","volume":"110","author":"RM Glasspool","year":"2014","unstructured":"Glasspool RM, Brown R, Gore ME, Rustin GJ, McNeish IA, Wilson RH, Pledge S, Paul J, Mackean M, Hall GD, et al. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2\u2019-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. Br J Cancer. 2014;110(8):1923\u20139.","journal-title":"Br J Cancer"},{"issue":"8","key":"6508_CR467","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1002\/cncr.25701","volume":"117","author":"S Fu","year":"2011","unstructured":"Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, Azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011;117(8):1661\u20139.","journal-title":"Cancer"},{"issue":"2","key":"6508_CR468","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.ygyno.2022.03.005","volume":"165","author":"JI Shim","year":"2022","unstructured":"Shim JI, Ryu JY, Jeong SY, Cho YJ, Choi JJ, Hwang JR, Choi JY, Sa JK, Lee JW. Combination effect of Poly (ADP-ribose) Polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer. Gynecol Oncol. 2022;165(2):270\u201380.","journal-title":"Gynecol Oncol"},{"issue":"13","key":"6508_CR469","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-18-0204","volume":"24","author":"N Pulliam","year":"2018","unstructured":"Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, Lyons J, Baylin SB, Matei D, Nakshatri H, et al. An effective Epigenetic-PARP inhibitor combination therapy for breast and ovarian cancers independent of BRCA mutations. Clin Cancer Res. 2018;24(13):3163\u201375.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06508-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06508-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06508-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T13:06:56Z","timestamp":1747228016000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06508-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":469,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6508"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06508-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"539"}}